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Zika virus (ZIKV), a member of the genus Flavivirus, has become a major 
public health concern since 2007. During the most recent 2015 outbreak, ZIKV 
rapidly spread from South America to over 84 countries and territories across the 
world in two years. ZIKV has also been associated with previously 
uncharacterized neurological manifestations during the 2013 and 2015 
outbreaks. The novel manifestations include Guillain-Barré Syndrome (GBS) in 
adults and Congenital Zika Syndrome (CZS) in newborns. GBS is a progressive 
paralysis caused by damage to the peripheral nervous system; while CZS is an 
all-encompassing term for the severe neurological and developmental 
complications observed in newborns infected with ZIKV in utero. The exceptional 
rate of spread and unique neurological involvement observed during recent 
outbreaks has established a significant demand to expand knowledge on ZIKV 
virulence and pathology in humans and other species that could serve as 
disease models. To date, only three mammalian species: the rhesus macaque 
(Macaca mulatta), guinea pig (Cavia porcellus), and laboratory mouse (Mus 
musculus) have been employed to study ZIKV pathology. Of the three 




a genetically-modified Type I Interferon (IFN) deficient laboratory mouse. Use of 
this model provides utility by recapitulating human-like disease; however, the 
host immune response of an immunodeficient animal does not accurately reflect 
an immunocompetent human immune response. The drawbacks created by the 
use of immunodeficient animal necessitate the development of a model where 
disease and the host immune response mirror human infections. Therefore, the 
current study looks to supplement the lack of ZIKV research across diverse 
species and provide the pilot data for justifying further research of the selected 
species as an immunocompetent animal model. This project examined ZIKV 
susceptibility and the host cell response of three primary cell culture types 
derived from less-conventional, yet immunocompetent, models of disease 
resistance or pathology; the deer mouse (Peromyscus maniculatus), Jamaican 
fruit bats (Artibeus jamaicensis) and Syrian golden hamster (Mesocricetus 
auratus). In the current study, we show that primary cell cultures derived from all 
three animal models are susceptibility to ZIKV infection. Between the three 
selected animal models, primary cell cultures from Jamaican fruit bats and Syrian 
golden hamsters demonstrated the highest permissibility to ZIKV replication and 
viral shedding. We also provide insight into the host cell Type I IFN immune 
response by elucidating the differential regulation of JAK1, STAT1, Oas1b and 
ISG15 steady state mRNA levels in response to ZIKV infection. As a whole, our 
findings supplement the lack of information of ZIKV research across a diversity of  
species and provides the pilot data required to warrant further investigation into 
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CHAPTER I  
INTRODUCTION AND REVIEW OF LITERATURE 
Flaviviruses 
The Flavivirus genus is one of four genera belonging to the family 
Flaviviridae. The genus is a widely diverse group comprised of 53 recognized 
viruses with over 40 members cited as human pathogens [1, 2]. Within the 
Flavivirus genus, members are grouped into three subgroups reflecting the virus-
vector-transmission route. The subgroups include arthropod-borne viruses 
(arboviruses), insect specific viruses, and no known vector viruses [1]. The 
arbovirus subgroup, which includes ZIKV, is comprised of flaviviruses that are 
primarily transmitted by arthropod vectors such as mosquitoes and ticks.  Other 
notable human pathogens comprising the arbovirus subgroup include yellow 
fever virus (YFV), dengue virus (DENV), Japanese encephalitis virus (JEV), Tick-
borne encephalitis virus (TBEV), and West Nile Virus (WNV) [3, 4]. Human 
infections with arboviruses of the flavivirus genus can manifest in a wide range of 
clinical symptoms and complications ranging from an asymptomatic or mild 
febrile illness, to severe hemorrhagic fever, encephalitis, and developmental 
abnormalities in children [5, 6]. Regarding epidemiology, the Flavivirus genus is 
the most relevant genus of viruses regarding the state of public health in tropical 
and subtropical regions of the world due to the burden generated by DENV, 




endemic range covers over 100 countries and 250-530 million cases of DENV 
infection occur worldwide every year. In 2016, over 3.34 million cases were 
reported in the Americas, South East-Asia and the Western Pacific. The Centers 
for Disease Control and Prevention also estimates that 100 million people will 
have symptomatic DENV infections and 22,000 deaths will occur every year due 
to DENV hemorrhagic fever [7, 8]. Between 1999-2018 WNV generated over 
50,000 cases in the United States alone. Of the reported WNV cases, 24,657 
cases manifested with neurological symptoms and over 2,000 deaths occurred 
from WNV infection [9]. Although YFV does not generate a considerable burden 
in countries like the U.S., it poses a considerable threat to countries in Africa and 
Central and South America. The WHO reports that 40 countries, 27 in Africa and 
13 in the Americas, are at high risk for YFV epidemics. In 2013, the lack of prior 
immunization in central and east Africa allowed for a major outbreak to occur 
resulting in an estimated 84,000-170,000 YFV severe cases and 29,000-60,000 
deaths [10]. Unfortunately, the burden to global health posed by these members 
of the Flavivirus genus will most likely increase in the oncoming years due to 
increasing vector ranges, a lack available vaccines for many of the viruses, and 
the scarcity of efficacious therapeutic treatments. The reality of the situation 
regarding the flaviviruses prompts a need to elucidate the nature of these viruses 
in order to effectively combat the significant threat they pose to the future of 






Structure and Replication 
Flaviviruses are enveloped positive sense Ribonucleic Acid (RNA) viruses 
comprised of  approximately 11 kilobases containing a single open reading 
frame. The single open reading frame is flanked at the 5’ and 3’ end by two short 
noncoding regions designated as the untranslated regions [2].The flavivirus life 
cycle is initiated by the attachment and entry of a mature virion into a susceptible 
host cell via Clathrin-mediated endocytosis. Clathrin-mediated endocytosis is a 
trafficking mechanism of the cell typically involved in nutrient uptake and cell 
signaling from the cell surface to the interior of the cell. ZIKV, along with other 
flaviviruses hijack the endocytic pathway as a means to gain entry into the host 
cell [11]. Currently, researchers hypothesize that flaviviruses gain access to a 
clathrin coated pit by rolling on the cell surface after loosely interacting with 
glycosaminoglycans (GAGs). GAGs are negatively charged low affinity 
attachment factors such as heparin sulfate or chondroitin sulfate [11, 12]. The 
flavivirus virions will roll on the cell until they come into contact with their 
respective entry receptor located within the clathrin-coated pits. After entry 
receptor attachment and clathrin-mediated endocytosis, proton pumps in the 
cell’s endosomes will generate a drop in pH, which will trigger a conformational 
rearrangement of the viral envelope protein (E protein) to allow for fusion of the 
viral and endosomal membranes. The fusion of the membranes triggers the 
release of the viral capsid into the cytoplasm. Once the viral capsid is in the 
cytoplasm, it will un-coat and release the positive sense single stranded RNA 




host ribosomes to initiate translation. The flaviviral genome is translated into a 
single polyprotein and it is co- and post-transitionally cleaved by host and viral 
proteases into three structural and seven nonstructural proteins [4, 13-15]. The 
structural proteins include the capsid (C), pre-membrane/membrane (prM/M), 
and envelope (E). The C, M, and E proteins form the structural components of a 
mature virion, mediate attachment/entry into a cell, and protect the viral genome 
outside of the host cell. The non-structural proteins, on the other hand, are 
implicated in the replication of the viral genome, virus assembly, polyprotein 
processing, and most relevant to the this research project, the modulation of host 
cell immune response. The flaviviral non-structural proteins are designated as 
the NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 proteins [4, 14, 15].  
Along with translation of the viral proteins, the replication of the viral 
genome and assembly of progeny virions will occur within invaginations of the 
endoplasmic reticulum known as vesicle packets. The vesicle packets are an 
important component for evasion of the host immune response early on during 
an infection due to their capacity to “hide” the exposed viral RNA from host 
immune sensory mechanisms, such as Retinoic acid-inducible gene-I-like 
receptors (RLRs) [14, 16]. Within the vesicle packets, the positive sense RNA 
genome will initially be transcribed into a negative sense RNA strand by the 
RNA-dependent RNA polymerase, NS5, that will be used a template for 
transcribing the positive sense RNA genome for the progeny virus. During 
transcription, the viral genome will be capped with a methyl guanosine 




C and prM proteins have been translated, the newly capped viral genome will 
interact with C proteins that have aggregated on the cytoplasmic side of the ER 
and will bud into the lumen of the ER. The newly formed immature virion will be 
covered with prM and E proteins that were present on the lumen side of the ER 
[13, 14]. An immature virion is distinguished from a mature virion by the presence 
of un-cleaved pre-membrane protein (prM). The presence of the prM protein is 
vital during the transit through the secretory pathway, because the prM protein 
prevents the E protein from fusing with the ER and Golgi apparatus’ membrane 
[17]. As the immature virion makes its way through the Golgi apparatus, the 
cellular protease, furin, will cleave the prM protein into pr and M. The cleavage of 
the prM protein will generate a confirmation change of the E protein from a 
heterodimer with the prM protein to a E protein homodimer. The new 
confirmation signifies a fully mature virion that can be transported to the plasma 
membrane to be released from the host cell via exocytosis [4, 14-17]. The 
released mature virion will have a diameter of ~50 nm, a membrane taken from 
the host cell endoplasmic reticulum, and a smooth surface comprised of E 
proteins in a herringbone pattern [18].  The mature virion will remain in the 
extracellular environment until it makes contact with the receptor of another 
susceptible cell, wherein it will be endocytosis and the viral replication process 
will commence again. Figure 1.1 displays an overview of the flavivirus life cycle 





Figure 1.1: An overview of the flavivirus replication cycle. (1) The 
attachment of a virion to a species-specific entry receptor. (2) The drop in pH 
within the host cell endosome mediated by protons being pumped into the 
endosome. (3) The drop in pH allows for the viral E protein to fuse with the 
endosomal membrane, allowing for the release of the viral RNA into the host cell. 
(4/5) The +ssRNA will travel to the endoplasmic reticulum where it is replicated 
and translated into the single polyprotein. (6) The newly synthesized +ssRNA 
and structural proteins will form an immature virion that will bud out of ER. (7) 
The immature virion will traffic through the trans-Golgi network where it will be 
cleaved by host cell proteases to transition into a mature virion. (8) The mature 




As of November 2017, commercially available vaccines exist for Dengue 
virus (DENV), yellow fever virus (YFV), Japanese encephalitis virus (JEV), West 




YFV, JEV, TBEV all provide efficacious vaccine protection for human populations 
[19]. The YFV vaccine, YFV 17D, is a live attenuated vaccine that was developed 
through serial passages of an isolated YFV sample in 1937 by Max Theiler. 
Since its development, over 500 million individuals have been vaccinated with 
the YFV 17D vaccine and the efficacy has been shown to be 98% effective for at 
least 10 years. The most current JEV vaccine, a live attenuated SA-14-14-2 
strain, was licensed in 1988 and has been shown to be 88-96% effective [4]. The 
TBEV vaccine is a highly purified formalin-inactivated whole virus vaccine.  The 
vaccine is produced in Western Europe and Russia, and has been shown to be 
98% effective at preventing disease for up to 3 years [4, 19].  
Dengvaxia, the only licensed DENV vaccine, has had a number of issues 
in its application, such as an uncertainty regarding the correlate of protection 
over time and against different DENV serotypes. In two phase III clinical trials, 
the pooled vaccine efficacy was only 59.2%. The efficacy also varied by 
serotype, with a range of 43-76.9 % (DENV serotypes 1-4).The suboptimal 
performance by Dengvaxia has prompted researchers to continue to pursue 
alternative vaccine candidates that offer a higher confidence of protection in 
humans. 
Similar to DENV, a vaccine for WNV does exist, but the vaccine is only 
available for application in the veterinary field. A formalin-inactivated vaccine has 
been developed and licensed in the early 2000’s for preventing WNV disease in 




chimeric vaccine expressing WNV antigens, has been shown to induce high titers 
of neutralizing antibodies and is currently in Phase III clinical trials [19].  
To date, there are still no commercially available vaccines or therapeutic 
treatments against ZIKV. The ongoing development of a ZIKV vaccine has 
generated over 50 vaccine candidates that are currently undergoing clinical trials 
[19-22]. Candidate vaccines in phase I or II of clinical trials include: inactivated 
whole viruses, recombinant measles viral vector-based vaccines, 
Deoxyribonucleic Acid (DNA) and messenger RNA (mRNA) vaccines, and a 
unique mosquito viral vector-based vaccine [22].  According to the World Health 
Organization, only two of the aforementioned candidate vaccines have made it to 
phase II of clinical trials. The two candidate vaccines include a mRNA vaccine, 
mRNA-1325, and a DNA vaccine, VRC-ZKADNA090-00-VP [23]. The mRNA 
vaccine, developed by Moderna Therapeutics, is a mRNA vaccine encapsulated 
in lipid nanoparticles. Trials with the vaccine have demonstrated complete 
protection against ZIKV challenge in AG129 mice (both mother and fetal 
progeny) and rhesus macaques. The DNA vaccine, developed by the National 
Institute of Allergy and Infectious Disease Vaccine Research Center, expresses 
the ZIKV pre-membrane and envelope proteins of the French Polynesia isolate 
(H/PF/2013). Previous studies with the vaccine have demonstrated 
immunogenicity in mice and monkeys [22]. The progress regarding ZIKV vaccine 
development is promising, but there is still a considerable amount of research 
and clinical trials required before a commercially available vaccine will be offered. 




flaviviral vaccines, puts the licensure of a ZIKV vaccine between 2022-2023 [22]. 
The United States Food and Drug Administration approved ZIKV vaccine timeline 
and lack of efficacious vaccines for WNV and DENV generates a necessity to 
better understand flaviviral pathogenesis. Elucidating the vital components of 
their pathogenesis would provide insight into avenues for increasing the efficacy 
of the vaccines, reducing the timelines required to create effective vaccines, and 
aiding in the development of therapeutic treatments.  
History/Epidemiology of Zika Virus 
Zika virus (ZIKV) was first isolated in 1947 during a routine surveillance for 
yellow fever virus. The first isolate, MR766, was isolated from the serum of a 
sentinel rhesus macaque in the Zika forest of Uganda. After the initial isolation, 
ZIKV was isolated a second time from a pool of Aedes africanus mosquitos 
collected in the Zika Forest in 1948 [24].The first reported case of human ZIKV 
infection was reported by David Ian Hewitt (D.I.H.) Simpson in Uganda in 1964. 
The account written by Simpson himself described the clinical symptoms that he 
suffered during the course of the ZIKV infection. He contracted the viral infection 
during a surveillance mission to isolate Zika virus from A. africanus between 
1962-1963 [25, 26]. Although ZIKV was discovered in 1947, the first major ZIKV 
outbreak did not occur until 60 years after the initial isolation. Prior to the first 
major outbreak, ZIKV circulated in Africa and Asia generating sporadic cases of 
infection. During the 60 year circulation period, only 14 cases of symptomatic 
infection were reported in humans [27]. However, serological surveys conducted 




distribution of ZIKV. In 1966, the presence of ZIKV in Asia was further confirmed 
by isolation from an Aedes aegypti mosquito [24, 28]. 
In 2007, the first major ZIKV outbreak occurred on Yap Island, a 
Federated State of Micronesia. The outbreak was estimated to effect ~73% of the 
roughly 7,000 inhabitants of the island. Of the affected population, approximately 
18% manifested with clinical symptoms. The clinical symptoms observed during 
the outbreak included a mild febrile illness, a maculopapular rash, arthralgia and 
conjunctivitis [28, 29]. One year later, the first case of potential ZIKV sexual 
transmission was reported. Two American virologists working in southeast 
Senegal returned to the U.S. and began suffering from rash, headache, fatigue, 
arthralgia, and haematospermia (only one individual). Serological samples taken 
from both individuals indicated that the most probable causative agent was Zika 
virus. Soon after returning, the wife of one of the virologists also began to suffer 
from the same symptoms. Investigation into the route of transmission concluded 
that the most probable route was either through saliva or sexual contact. The 
subsequent detection of high ZIKV titers and ZIKV RNA in semen has supported 
the viability of ZIKV sexual transmission [24].  
The second major ZIKV outbreak occurred between 2013 and 2014 on the 
French Polynesian islands. During the course of the outbreak, approximately 
11% of the population was estimated to have sought out treatment for suspected 
ZIKV infections. Although most of the symptomatic cases presented with the 
same febrile illness observed in the 2007 outbreak, the defining feature of the 




with Guillain-Barré Syndrome (GBS) [21, 24, 28, 29]. Post-outbreak studies of 
epidemiological data revealed that the cases of GBS during the outbreak rose by 
a staggering ~20 fold increase [28]. Either shortly after or during the 2014 
outbreak, imported cases of ZIKV were reported in New Caledonia, Easter 
Island, the Cook islands, Australia, Italy, Japan and Norway [28]. By mid-January 
2014, 1,385 laboratory confirmed cases of ZIKV infection on the island of New 
Caledonia indicated that ZIKV was spreading and had become endemic on 
neighboring islands in the Pacific [24].   
In March 2015, seven cases of Reverse Transcriptase-quantitative 
Polymerase Chain Reaction (RT-qPCR) confirmed ZIKV infections were reported 
in Bahia, Brazil. The confirmed cases were the first reported cases of the most 
recent 2015 outbreak. Sequence analysis of the ZIKV envelope protein from an 
isolated sample revealed a 99% identity with the 2013 French Polynesian isolate 
[24]. Phylogenetic and molecular clock analysis indicate that the outbreak was 
initiated by a single introduction of ZIKV into Brazil. Epidemiologist postulate that 
the virus was likely brought into the country by a French Polynesian traveler who 
had recently stopped at Easter Island [29]. Within one year of the initial isolation, 
ZIKV had spread from Bahia to at least 14 states of Brazil. Along with an 
exceptional rate of spread, the 2015 outbreak was characterized by an 
unforeseen increase of microcephaly cases of newborn infants in regions with 
local ZIKV transmission. The presence of microcephaly during the 2015 
prompted a retrospective study on the 2007 French Polynesian outbreak 




in the number of cases of microcephaly and other fetal abnormalities that were 
observed during the 2013/2014 outbreak [27, 28].  
In December 2015, the first case of local ZIKV transmission in a U.S. 
territory, Puerto Rico, was reported. Subsequently, two U.S. states, Florida and 
Texas, reported autochthonous transmission of ZIKV in 2016 [30]. By November 
2016, 48 countries and territories in the Americas had reported autochthonous 
transmission of ZIKV [28]. The continual spread and association with fetal 
abnormalities prompted the World Health Organization to declare a state of 
Public Health Emergency of International Concern from February 1st 2016 to 
November 18th 2016 regarding ZIKV [21]. The latest World Health Organization 
ZIKV epidemiology situation report, published in July of 2019, reports that ZIKV 
has spread to 87 countries and territories across the world with vector borne 
ZIKV transmission since the beginning of the 2015 outbreak [31]. Although the 
number of reported ZIKV cases have significantly decreased since 2017, there 
are still 68 countries on the Centers for Disease Control and Prevention’s travel 
notice for risk of ZIKV transmission [32, 33]. The extensive range of ZIKV, 
association with severe neurological manifestations, and the World Health 
Organization’s declaration of a global health crisis has stimulated novel research 
that has supplemented the collective knowledge on ZIKV, but a large number of 
questions and issues still remain that must be addressed. 
Zika Virus Isolates 
During the 60-year period between 1947 and 2007, ZIKV remained 




The continual circulation of ZIKV during the period allowed the virus to diverge 
into the two distinct lineages that are recognized today. However, a recent 
phylogenetic analysis by Shen et al. has provided evidence for a third lineage. 
The proposed lineage would create a spilt in the African lineage into the West 
African (Nigerian cluster) and East African (MR766 cluster) lineages [34, 35]. It is 
important to note which lineage is being utilized in a study, because previous 
research has indicated significant differences in the replication kinetics and 
virulence between isolates from different lineages [21, 36].  
In a study with Stat2-/- mice, Tripathi et al. compared ZIKV infections with 5 
isolates from a range of geographically and temporally relevant origins [21]. The 
results of the study indicated that there were considerable differences between 
the two distinct lineages. African lineage isolates are generally more virulent with 
a rapid onset of severe neurological symptoms in Stat2-/- mice. African strains 
also induced a high level of inflammatory cytokines and markers associated with 
cellular infiltration in the infected mice. Isolates of the Asian lineage, on the other 
hand, were generally less virulent and presented with a delayed onset of 
symptoms. However, the delayed onset of symptoms also coincided with a more 
prolonged neurological infection [21]. 
Bowen et al. also arrived at a similar conclusion in a study involving  ZIKV 
and human dendritic cells (DCs) [37]. Four isolates, 2 of each lineage, were 
employed in their study to represent “contemporary and historic” isolates of both 
lineages. Results of the study demonstrated that both African and Asian ZIKV 




replication kinetics and the immune response/suppression were notably different 
between the two lineages. The African lineage replicated at a faster rate in the 
human DCs with a higher overall magnitude in the viral load during infection 
compared to the Asian lineage isolates. As well, human DCs cell death was only 
observed in cultures infected with African lineage isolates [37].  
Currently, there are over 290 ZIKV isolate genomes available on NCBI. Of 
those genomes, 256 were isolated from humans, 36 from mosquitos, and 8 from 
Non-Human Primates and cell culture [29]. The PRVABC59 isolate utilized in the 
current study belongs to the Asian lineage and was isolated from a patient in 
Puerto Rico during the most recent 2015 outbreak. There is a 99.6% nucleotide 
sequence homology and 99.9% amino acid homology between the selected 
isolate and the initial 2015 isolate from Bahia, Brazil [38]. The PRVABC59 
isolate, as with many previous studies, has been chosen for the current study as 
the ideal candidate for elucidating information regarding the emerging ZIKV 
isolates that have caused the concerning rise in the associated neurological 
manifestations, novel modes of transmission, and the alarmingly rapid 
dissemination of the virus across the world in less than a year [37, 39-41].  
Transmission of Zika Virus 
 As an arthropod-borne (arbo) virus, ZIKV, is primarily transmitted through 
the feeding of hematophagous mosquitos. The two main vectors of ZIKV 
transmission are Aedes aegypti and Aedes albopictus. ZIKV has also been 
demonstrated to infect and replicate in the midgut and salivary glands of Culex 




controversial and require further evaluation [42]. Aedes aegypti is considered to 
be the primary vector of ZIKV, because previous research has demonstrated the 
susceptibility of the mosquitos and successful viral isolation from populations of 
Aedes aegypti [43]. Aedes aegypti are also thought to have a higher capacity as 
a vector because they will primarily bite humans, feed from multiple humans 
during a single blood meal, and live in close proximity to humans [28, 44]. Both 
species of mosquito are widely distributed throughout tropical and subtropical 
regions of the world. Researchers have also noted that the wide distribution of 
both mosquitos will likely increase over the next decade due to global warming 
into regions previously protected by the limited tropical and subtropical range of 
the vectors [45, 46]. The increased range will put more individuals at risk for local 
transmission of flaviviruses carried by both vectors including ZIKV, YFV and 
DENV.  
 Non-vector-borne ZIKV transmission has been documented through 
multiple routes including sexual transmission, in utero transmission from a 
mother to progeny, and transmission of bodily fluids via breast milk or blood 
transfusions [24, 28]. Since the first reported cases of potential sexual ZIKV 
transmission, cases have revealed that transmission can occur from both sexes. 
The highest potential for sexual transmission is estimated to be within the first 12 
days after symptom manifestation [47]. Of the potential transmission types, male-
to-female transmission has been noted to occur with the highest frequency [28]. 
In a review of reported cases of sexual transmission, 94% (34 out of 36) of cases 




transmission [47]. In an evaluation of prolonged viral shedding in the male 
reproductive tract, viral RNA was detected in semen up to 9 months after the 
initial infection. Although evidence shows a prolonged shedding of viral RNA, 
levels of infectious virus in semen rapidly decreased during the first 3 months 
after the symptomatic phase of the infection [48]. Due to the higher frequency of 
males being involved in sexual transmission, the majority of the research 
regarding sexual transmission has focused on males. However, reported cases 
of ZIKV have demonstrated that viral RNA can be detected up to 37 days in fluid 
from the female genital tract [47].  
 The majority of research regarding female’s capacity to transmit ZIKV has 
focused on the vertical transmission from a mother to her progeny. In trans 
placental transmission, a pregnant mother with viremia can transmit the ZIKV 
through the placenta to her child while in the child is in utero. Interestingly, the 
pathway in which the ZIKV is able to infect and gain access to the placenta, and 
subsequently the fetus, is still not completely understood. Previous research has 
demonstrated that ZIKV isolates in the Asian lineage have the capacity to infect 
the human decidua, trophoblasts, and umbilical cord tissues. Access these tissue 
is thought to  allow for the virus to gain access to the fetus and lead to apoptosis 
of chorionic villi, which would result in the breakdown of the fetal blood/nutrient 
supply [29, 49, 50]. Conversely, recent studies have demonstrated that primary 
human trophoblast cells effectively block ZIKV replication and fetal transmission 
via the breakdown of the trophoblast mediated barrier by constitutively 




al. provides evidence for cell-associated transport to the fetal blood supply 
through ZIKV susceptible human Hofbauer cells [53]. Therefore, the transmission 
of ZIKV to the fetus could be possible without the required breakdown in the 
human trophoblast mediated fetal blood supply barrier. The mechanism by which 
ZIKV gains access to the fetus from the mother may not be abundantly clear at 
this time, but it is apparent that the ZIKV has adapted a unique mechanism for 
subverting human reproductive barriers to cause the severe developmental 
abnormalities that have been associated with the virus.  
Novel Neurological Involvement 
The common clinical manifestations of Zika virus infection, known as Zika 
fever, include  fever, maculopapular rash, arthralgia, myalgia, headache, and 
conjunctivitis [21, 54]. The mild febrile has an established incubation period of 3-
14 days with an average of 6 days. The onset of clinical symptoms will typically 
occur within one week of inoculation but have also been observed to manifest up 
to two weeks after the initial inoculation. Symptomatic infections are self-limiting 
and will typically subside after two weeks [55].   
Since the 2013 and 2015 outbreaks, ZIKV has also been associated with 
novel neurological manifestations that include Guillain Barré Syndrome in adults 
and Congenital Zika Virus Syndrome (CZS) in newborns. Guillain Barré 
Syndrome, a neurological sequelae of ZIKV infections occurs after 
convalescence of the symptoms. Guillain-Barré syndrome is a progressive form 
of flaccid paralysis that is caused by autoimmune damage to the myelin sheaths 




encompass all of the developmental abnormalities associated with in utero ZIKV 
infections, can manifest as a spontaneous abortion, ocular abnormalities, 
microcephaly, hydrocephaly, microcephaly, abnormal joint and smooth muscle 
development, and intrauterine growth restriction [27, 54]. 
Zika Virus Receptor and Cell Tropism 
ZIKV entry into the host cell is mediated by the interaction between the N-
glycan conjugated to the ZIKV E protein (at Asn154) and host cell receptors [11, 
56, 57]. However, the specific receptor involved in the interaction is still highly 
debated. Due to the extensive list of susceptible cell types, it has been difficult for 
researchers to identify a single cell receptor as the main culprit for ZIKV entry. 
Therefore, the leading hypothesis is that ZIKV utilizes a broad number of cell 
receptors to mediate its capacity to infect multiple different cell lines. In humans, 
ZIKV tissue tropism has been observed in neural, ocular, renal, testicular, 
uterine, vaginal, and placental tissues. As well, ZIKV has also been detected in 
multiple bodily fluids including tears, saliva, semen, cervical mucus, and urine 
[58-60]. The following sections will discuss the leading candidates for the 
proposed entry cell receptors.  
The most predominant candidate in ZIKV entry receptor research is AXL. 
AXL or Tyro7 is a member of the TAM family of receptor tyrosine kinases. As a 
member of the TAM family, AXL is thought to be involved in cell proliferation, 
migration, invasion, and survival signaling for a number of different cell types [61, 
62]. AXL has also been shown to be involved in the clearance of apoptotic cells, 




related TIM receptor counterparts, TAM receptors do not bind directly to viral 
glycoproteins. AXL, like other TAM receptors, will indirectly interact with the 
glycosylated ZIKV E protein binding site through the mediator protein Gas6. 
Relevant cell types expressing AXL in regard to ZIKV infections include: radial 
glial cells, astrocytes, microglial cells, endothelial cells, ocular progenitor cells, 
Sertoli cells [39, 62, 63].  
The basis for implicating AXL as the entry receptor is instigated by a 
considerable amount of previous research conducted in primary human cells [25, 
62-66]. Liu et al. has demonstrated ZIKV’s association with AXL by blocking the 
receptor on human vascular endothelial cells (HUVEC) with an antibody that 
recognizes the extracellular portion of AXL. Two ZIKV isolates (MR766 and 
PRVABC59) were unable to infect the HUVEC cell cultures after treatment with 
the antibody. Along with these finds, the authors also demonstrated that 239T 
cells with ectopic expression of AXL were susceptible to ZIKV infection and a 
mutation (K567R) that prevents the phosphorylation and signaling of AXL 
disrupted ZIKV susceptibility in the 239T cells [65].  
In agreement with Liu et al.’s findings, Persuad et al. also demonstrated 
that AXL deficient human (malignant) fibroblast cell lines, HT1080, were not 
permissive to ZIKV infection. The researchers developed AXL knockout lines of 
HT1080 cells with the CRISPR/Cas9 system and experimentally infected them 
with increasing Multiplicity of Infections (MOIs) of ZIKV (MR766 isolate).  The two 
developed HT1080 knockout lines, clones 3-II and 1-1V, were not susceptible to 




line that expressed functional AXL receptors showed ZIKV infection at MOIs of 
0.5-10 [66]. The protection against ZIKV infection in AXL negative lines has also 
been demonstrated by previous research groups in primary human astrocytes 
and sertoli cells, and immortalized microglial cells (CHME3),  glioblastoma cells 
(U87), and human epithelial cells (HeLa) [63, 66-71].  
In contradiction to the findings on AXL’s importance, recent studies have 
provided surmounting evidence that AXL is not indispensable for ZIKV [68, 72]. 
Instead, researchers have proposed that ZIKV will utilize different entry receptors 
depending on the cell type in question. In a study focused on ZIKV in skin cells, 
Hamel et al. note that DC-SIGN and Tyro3 were mediators for ZIKV entry into 
host cells [25, 65]. Hamel’s research group utilized a series of HEK293T cells 
expressing DC-SIGN, TIM-1 ,TIM-4 and Tyro3 to determine the importance of the 
expressed receptors on ZIKV susceptibility. The researchers found that the cell 
lines expressing DC-SIGN and Tyro3 were highly permissive to ZIKV infection 
[73]. Tyro3, like AXL, is a TAM receptor that is expressed on a wide range of cell 
types. Conversely, DC-SIGN is a significant finding as a ZIKV receptor due to the 
receptor’s specific expression on macrophages and immature dendritic cells. In 
the typical mode of transmission, a mosquito will transmit the virus through its 
saliva via a hematophagous feeding. During the feeding, the virus laden saliva 
will be delivered to the dermis and epidermis of the new host. The area around 
initial infection site will be full of immune migratory cells like dendritic cells and 
macrophages. The close proximity of DC-SIGN expressing cells provides the 




utilize the migratory facet of the immune cells to gain access to the bloodstream 
and other tropic tissues [74].  
TIM-1 was also shown to mediate ZIKV entry into HEK293T cells, but at a 
significantly lower effect in relation to DC-SIGN and Tyro3. Tabata et al. 
reinforced these findings by using duramycin to block TIM-1 activity in human 
chronic villus explants. Duramycin is phosphatidylethanolamine binding antibiotic 
that disrupts membrane function. The antibiotic  was previously demonstrated to 
disrupt DENV infection through the same TIM-1 blocking mechanism. The results 
of the study indicated that duramycin mediated disruption of TIM-1 effectively 
blocked ZIKV infection in the explanted placental tissue. TIM-1 is a glycoprotein 
that interacts with the phosphotidylserine displayed on a viral membrane [11, 73, 
75]. The glycoprotein receptor is expressed on Hofbauer macrophages, 
endothelial cells, and cytotrophoblasts [58]. As discussed in the transmission of 
ZIKV, the aforementioned cell types are found in the uterus and placental region 
of humans. The connection of these reproductive associated cells expressing the 
potential entry receptors for ZIKV into placenta and uterine tissue play an 
important role in understanding the mechanism ZIKV utilized to generate the 
vertical transmission from a mother to her progeny.  
Immune Evasion of Zika Virus  
The Type I Interferon (IFN) pathway is a vital component of the innate 
immune response against viral replication through the induction of a potent 
antiviral state in infected cells which is characterized by a halt in RNA and protein 




the Type I IFN response through the the cell’s detection of pathogen associated 
molecular patterns (PAMPs) using pattern recognition receptors (PRRs). PRRs 
include innate immune receptors such as Retinoic acid-inducible gene-I-like 
receptors (RLR), Toll-like receptors (TLR 1 -10), cGas, IFI16, and many more. Of 
the RLRs, RIG-I is considered to be the major cytoplasmic sensor involved in the 
initial detection of flaviviruses. MDA5, another RLR, is also involved in flavivirus 
detection, but previous research has indicated that MDA5 knockout MEF cells 
are still able to efficiently respond to DENV and WNV infections [77-80]. 
Therefore, MDA5’s Type I IFN response involvement is thought to be more of a 
secondary receptor role in response to flavivirus infection.  
As members of the RLR family, RIG-I and MDA5 are both DExD/H box 
RNA helicases that bind and unwind RNA. The major difference between RIG-I 
and MDA5 is their RNA recognition preferences. MDA5 has been shown to 
preferentially bind to high molecular dsRNA poly I:C fragments, whereas RIG-I 
preferentially binds to shorter 5’ triphosphorylated double stranded and single 
stranded RNA fragments. Along with the DExD/H box domain, both RLRs have 
two tandem caspase activation and recruitment domains (CARD1 and 2 
domains) and a C-terminal repressor domain. After recognizing and binding to 
cystosolic viral RNA, RIG-I will alter its confirmation to expose the CARD 
domains. The exposed CARD domain permits the interaction of RIG-I with the 
Mitochondrial antiviral signaling adapter (MAVS). Association with MAVS (also 
known as IPS-1) recruits TANK-binding Kinase 1 (TBK1) to the signalosome and 




and traffic to the nucleus. Upon entering the nucleus, the IRF3 homodimer will 
lay down on the Type I IFN promoter region and act as a transcription factor for 
IFN a and IFN b. In order to maintain a prolonged activation of the RIG-I 
pathway, IRF7 will also be upregulated in response to a positive feedback loop 
after the expression of IFN-a and IFN-b has been initiated. IRF7 functions similar 
to IRF3 by forming homo and heterodimers (with IRF3) once it is phosphorylated 
by TBK1 to drive the Type I IFN expression [3, 30, 81, 82]. Figure 1.2 displays a 
visual representation of the activation the RIG-I and MDA5 pathway and 








           
Figure 1.2: Detection of viral RNA by Pattern Recognition Receptors 
(PRRs).  RIG-I and MDA5 are involved in the recognition of viral RNA during 
flavivirus infections. The RIG-I pathway is considered the predominant pathway 
activated by flaviviral RNA. Activation of the RIG-I pathway leads to the induction 
of Type I IFNs through the phosphorylation and subsequent activation of IRF-3 
and 7. The production of Type I IFNs induces an antiviral state within virally 
infected host cell. MDA5 is involved as a secondary measure to generate a 
prolonged activation of the Type I IFN response [82].  
 
The expressed IFN-a or IFN-b generated by the RIG-I and MDA5 pathway 
will bind to Type I IFN receptors on the expressing cell as well as neighboring 
cells. The Type I IFN receptor is a transmembrane Jak-Stat receptor with two 
subunits, IFNAR1 and 2. The binding of the ligand to the Type I IFN receptor will 
recruit JAK1 and Tyk2 to the receptor. The recruited JAK1 and Tyk2 will auto- 
and trans-phosphorylate each other and the IFNAR subunits. The fully activated 




proteins to the receptor. STAT1 is initially recruited and phosphorylated by JAK1, 
and Tyk2 follows suit by recruiting and phosphorylating STAT2. Consequently, 
the phosphorylated STAT proteins will heterodimerize and translocate to the 
nucleus where they will form a transcription complex with IRF9. The transcription 
complex, ISGF3, will bind to the IFN-stimulated response element (ISRE) to 
initiate the transcription of vital Interferon Stimulated Gene (ISG). ISGs encode 
for several hundred proteins involved in the innate antiviral immune response [3, 
20, 80, 83]. Figure 1.3 depicts each step of the Type I IFN pathway leading to the 







                   
Figure 1.3: The Type I Interferon pathway. Once the Type I IFNs are 
recognized by their respective Type I IFN receptor, the signaling pathway leads 
to the phosphorylation of STAT1 and 2. The phosphorylation of STAT1 and 2 
activates the signal transduction proteins leading to their heterodimerization. 
STAT1 and 2 will form a complex with IRF9, designated ISGF3, that will generate 
the induction of ISGs [84]. 
 
Due to the Type I IFN response’s capacity to induce an antiviral state in 
both the target cell and neighboring cells, flaviviruses have evolved a number of 
suppressive mechanisms to subvert the host cell’s immune response. The 
flavivirus components involved in suppression of the Type I IFN response include 
one or more non-structural proteins and the flavivirus 3’ untranslated region or 




Type I IFN response utilize shared components of flaviviruses, the suppressive 
mechanism is drastically different between members of the genus [3].  
As with other flaviviruses, the ZIKV sfRNA decreases degradation of 
uncapped viral RNA and dysregulates host cell mRNA stability by stalling the 
host cell ribonuclease, XRN1. The sfRNA has multiple hairpin structures that will 
cause the XRN1 to stall and become ineffective at degrading both viral and host 
cell RNA. The importance of the sfRNA’s XRN1 stalling activity has been 
elucidated for WNV, DENV and other notable members of the Flaviviridae family 
including Hepatitis C virus and bovine diarrheal virus [85]. Previous research 
regarding sfRNAs has also indicated that the untranslated RNA is also 
responsible for antagonizing the Type I IFN response directly in ZIKV, West Nile 
virus (WNV), Dengue virus (DENV), and Japanese encephalitis virus (JEV) 
infected cells. Unlike the shared stalling activity mechanism, the method by which 
the sfRNA antagonizes the type I IRN response differs between each flavivirus. 
DENV’s sfRNA binds to the RIG-I activing enzyme TRIM-25, effectively 
suppressing the activation of RIG-I dependent IFN production [86]. WNV and 
JEV’s sfRNA targets the RIG-I pathway downstream relative to DENV’s sfRNA 
by antagonizing IRF-3 and 7 [87, 88]. In contrast, ZIKV follows suit with DENV by 
antagonizing RIG-I and MDA-5’s induction of IFNs. However, the mechanism by 
which ZIKV suppresses both of these activation pathways is still unclear at this 
time [89].  
Along with the sfRNA mediated antagonism, NS1,NS2A, NS4B, NS5 and 




the Type I IFN response for one or more flaviviruses. To date, previous research 
has elucidated the importance of the NS1, NS2B-3, NS3, NS4B, and NS5 
proteins involvement in ZIKV’s antagonism of the type I IFN response at multiple 
junctions within the pathway [2, 3, 90]. During a ZIKV infection, NS1, NS2A and 
NS4B all target TBK1 to inhibit the synthesis of the downstream IFNs [20, 90]. 
Interestingly, Xia et al. demonstrate that a single mutation in the amino acid 
sequence of the NS1 protein (A188 to V) generates a significant difference in the 
proteins capacity to suppress the IFN response both in vitro and in vivo through 
TBK1 antagonism. After comparing pre-epidemic (prior to 2012) and post-
epidemic ZIKV isolates, the authors propose that the single amino acid mutation 
may be a contributing factor for the increased capacity of post-2012 ZIKV strains 
to cause major outbreaks [90]. However, more research will need to be 
conducted in order to fully understand how the single mutation affected ZIKV’s 
proclivity for generating epidemics. In comparison, NS4B and NS2A are also 
utilized by DENV, YFV and WNV, but the antagonizing proteins inhibit STAT1 
phosphorylation during all three viral infections. YFV also utilizes NS4B to 
interact with STING to block the stimulatory effects of the protein on RIG-I [3].  
NS2B-3 is the complex formed between the NS2B and NS3 proteins. 
During a flavivirus infection, the two proteins will form a stable complex that 
functions as a serine protease that will cleave both viral and host proteins. The 
effects of the NS2B-3 complex on the host cell response during a ZIKV infection 
are two-fold. During a ZIKV infection, the NS2B-3 complex will directly interact 




apoptotic pathways. By promoting the degradation of JAK1, NS2B-3 not only 
depletes the levels of the protein, but will consequently inhibit JAK1 and STAT1 
phosphorylation. The resulting suppression demonstrated by Wu et al. indicates 
that the markedly lower levels of phosphorylated JAK1 and STAT1 proteins 
significantly decreased the expression of multiple ISGs. NS2B-3’s secondary 
effect on the host cell response blocks the RLR- triggered apoptotic pathway by 
inhibiting the cleavage of caspase 3 and Poly ADP ribose polymerase (PARP). 
Wu et al. confirmed the effects of ZIKV on the RLR-triggered apoptotic pathway 
by exposing ZIKV infected HT180 cells to poly (I:C). Cell cultures at 24 and 48 
hours post infection showed lower poly (I:C) induced cell death compared to non-
infected cultures. The research group also confirmed that ZIKV infected cultures 
with higher amounts of NS2B-3 were more resistant to poly (I:C) induced 
cleavage of caspase 3 and PARP. However, the exact mechanism by which 
NS2B-3 is blocking the cleavage of capase 3 and PARP is still currently unclear. 
These findings suggest that NS2B-3 is a vital component for generating 
productive ZIKV infections through the reduction of ISG expression and 
protection of infected cells from RLR-triggered apoptosis [20].  
Between all of the flaviviral NS proteins involved in subverting the host cell 
immune response, NS5 is the most commonly utilized. During an flaviviral 
infection, NS5 functions as a methyltransferase and a RNA dependent RNA 
polymerase. NS5’s involvement in inhibiting the host cell response has been 
demonstrated for ZIKV, DENV, YFV, WNV, JEV, Tick-borne encephalitis virus 




the other NS proteins, the NS5 mechanism of antagonism is varied between the 
flaviviruses that employ it for immune suppression. WNV, TBEV, and LGTV’s 
NS5 targets the IFNAR1 receptor by dysregulating IFNAR1 maturation and 
reducing the receptors cell surface expression. The target of JEV’s NS5 protein 
is thought to be inhibition of JAK activation, but the mechanism for generating the 
inhibition is currently unclear. YFV, DENV and ZIKV’s NS5 protein shares a 
commonality in their target, STAT2, but the mechanism and host proteins 
involved in the antagonism diverge. DENV and YFV NS5 proteins both require 
host cell proteins, UBR4 and TRIM23 respectively, to carry their antagonistic 
effects [2]. However, the mechanism of action between DENV and YFV’s NS5 
protein differs in that DENV’s NS5 causes the proteosomal degradation of 
STAT2, while YFV’s NS5 suppresses the pathway downstream relative to DENV 
by inhibiting ISG translation [2, 3]. Similar to the DENV, the ZIKV NS5 protein will 
interact and lead to the proteosomal degradation of the human/primate STAT2 
protein. Interestingly, SPOV, a flavivirus belonging to the same serocomplex as 
ZIKV, does not have the same mechanism of antagonism or target regarding its 
NS5 protein. SPOV’s NS5 protein suppresses the induction of ISGs similar to 
YFV, but the target for generating this effect is still currently unknown [2]. Unlike 
DENV, ZIKV’s NS5 does not require the cooperation of the host protein UBR4, 
an E3 ubiquitin ligase, to effectively antagonize STAT2. During DENV’s NS5 
antagonism of STAT2, the NS5 protein acts as a bridge between UBR4 and 
STAT2. The interaction mediated by the DENV NS5 protein allows UBR4 to 




by promoting the degradation of STAT2 by host proteasomes like DENV, but 
identity of the cooperative host cell ubiquitin ligase involved in the process, or if 
ZIKV’s NS5 protein even requires a host cell protein to generate the antagonistic 
effects is still unclear at this time [2, 92, 93].  
The degradation of the STAT2 protein by ZIKV’s NS5, and the cooperative 
effects of the sfRNA and other NS proteins results in the effective inhibition of the 
Type I IFN response in primates. The inhibition of the Type I IFN response is 
required for ZIVK to generate a productive infection prior to the recognition and 
subsequent clearing of the infection by the adaptive immune response. 
Therefore, understanding and elucidating the mechanisms by which ZIKV 
generates the antagonism of the Type I IFN in humans, non-human primates and 
a diversity of other species is an important avenue of research for aiding in the 
development a more effective animal model and may lead to the discovery of 
effective therapeutic treatments against ZIKV and other flaviviruses.   
Current Zika Virus Animal Models 
A major component of vaccine and therapeutic treatment development is 
the availability of an animal model that has the capacity to recapitulate human 
disease in order to test the efficacy and safety of novel treatment options. Along 
with the capacity to recapitulate human disease an ideal animal model would be 
widely available, easy to handle, produce large litter sizes, have comparable 
anatomy and physiology to humans, and require minimal effort in housing and 




Dawley rats (Rattus norgevicus), are commonly used in viral and biomedical 
research due to their natural characteristics meeting the optimum criteria. 
Current ZIKV research has relied heavily upon type I IFN immunodeficient 
mice (Mus muscus) because of their ability to recapitulate the severe 
neurological manifestations observed in human infections [3, 20, 21, 27, 41, 93-
95]. Studies have relied on using Type I IFN immunodeficient mice as the 
primary ZIKV disease model due to key differences in the interaction between the 
human and mouse STAT2 protein with the ZIKV NS5 protein. The mouse STAT2 
protein, unlike human STAT2, is not antagonized by the ZIKV NS5 protein. An 
immunocompetent mouse with the unblocked STAT2 protein is able to mount a 
functional innate antiviral response to ZIKV infection [3, 83, 93]. Without 
effectively knocking out the ability of the mouse’s capacity to produce the Type I 
IFN response, the currently accepted ZIKV animal model would be ineffective at 
recapitulating a human ZIKV infection.  
Type I IFN immunodeficient mice are produced by single, double and triple 
knockouts in key proteins of the Type I IFN pathway. The genetic modification 
effectively depletes the animal’s ability to mount a functional Type I IFN immune 
response against ZIKV infection. The resulting animal model will present with 
viremia, high viral loads in multiple organs, severe neurological symptoms, and in 
some cases death [21, 27]. The wide availability, low maintenance cost and 
relatively effective recapitulation of human ZIKV infections of the immunodeficient 
mice is beneficial, but the use of an immunodeficient animal model in pathogen 




findings obtained from an animal with a disrupted immune response. As well, the 
outcome of death in many cases during ZIKV infection in the immunodeficient is 
arguably ineffective at recapitulating the human response since it is extremely 
rare for death to be the consequence. A considerable amount of virologist 
contest immunodeficient animal models arguing that conclusions drawn from the 
data are not applicable in real world scenarios. The concern regarding 
applicability stems from the fact that the research will be applying conclusions 
derived from the incomplete immune response of  the genetically altered mice to 
the competent immune response of a human during a ZIKV infection.  
It is important to note that three immunocompetent animal models have 
been utilized in previous research, the rhesus macaque (Macaca mullatta), 
Syrian golden hamsters, and guinea pigs (Cavia porcellus) [54, 96-98].The 
rhesus macaque model has precedence as a nonhuman primate ZIKV model 
that effectively recapitulates human symptoms, but the extreme lack of 
availability and substantial cost for a single animal makes their use in research 
highly impractical. Guinea pigs and Syrian golden hamsters, on the other hand 
are the most suitable candidates for a ZIKV animal model. However, the status of 
both animals as the accepted ZIKV model remains in the preliminary phase of 
development.  
Novel Animal Models and  
Primary Cell Lines 
 As noted above, very little research assessing the effects of ZIKV across a 
diversity of species has been conducted. Therefore, this study looks to expand 




examining the susceptibility and immune regulation of primary cell lines derived 
from three unique animal models. The deer mouse, Jamaican fruit bat, and 
Syrian golden hamster have been selected as the animal models for this study 
because of their ease of handling, minimal requirements for housing and 
availability at the University of Northern Colorado. From the selected mammals, 
three significant tissue types have been selected for assessment with ZIKV 
experimental infections. The primary cell lines established and evaluated during 
this study include mixed primary kidney and lung cell cultures, and primary 
hepatocyte cultures. The tissue types and animal models were selected for their 
employment in previous studies involving the permissibility and host cell 
response during ZIKV infection.  
Due to the established presence of ZIKV in the urine of humans and other 
susceptible species, multiple research groups have evaluated the tropism of 
ZIKV for kidney cells [59, 99, 100]. A recent study by Alcendor, J., demonstrates 
the permissiveness of human glomerular podocyte, renal glomerular endothelial 
cells, and mesangial cell cultures to ZIKV infection. ZIKV susceptibility of these 
cell types was confirmed in samples from all three cell types via 
immunofluorescent staining, Polymerase Chain Reaction (PCR) and Reverse 
Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) [59]. 
Diteepeng et al.’s findings also support for the kidney involvement during ZIKV 
infection by demonstrating the permissiveness of the Rhesus Macaque kidney 
cell line, LLC-MK2, to the virus. The study found that on average, 40% of the 




(Thailand, 2015; Asian lineage) by marking and sorting infected cells with a BD 
FACS cytometer and a mouse monoclonal pan flavivirus antibody [100]. 
The susceptibility of liver and lung cells to ZIKV infection have also been 
evaluated in previous research, albeit to a lesser extent, in human and non-
human cell lines. Using a shotgun approach, Chan et al. evaluated the 
susceptibility of 33 different immortalized cell lines derived from both human (18) 
and non-human (15) species. ZIKV susceptible cell lines were determined by 
immunofluorescent staining with a mouse antibody against the ZIKV NS1 protein 
and detection of viral RNA through probe based RT-qPCR. The results of both 
detection assays indicated susceptibility of human derived lung cultures, Calcu-3 
and HFL, and human derived hepatocyte cultures, Huh-7, to both PRVABC59 
and 976 Ugandan (Ugandan, 1976; African lineage) isolates [40]. The 
aforementioned study by Diteepeng et al. also evaluated the susceptibility of 11 
different human derived cell lines to the SV0010/15 and MR766 ZIKV isolates. 
The results of their investigation support the findings of Chan et al. by 
demonstrating the susceptibility of human derived lung cultures, A549, and 
human derived liver cultures, HEP3B and HepG2, to both ZIKV isolates [101]. 
These in vitro findings involving ZIKV, along with the well-established 
involvement of the lung tropism, during Dengue virus (DENV) infections, and the 
liver tropism, during yellow fever virus (YFV) and DENV infections, affords the 
basis by which the selected tissue types for establishing primary cell culture were 




The Syrian Golden hamster was selected as an attractive disease model 
for ZIKV due to their well-documented capacity to recapitulate human disease for 
a number of viral infections, including flaviviruses. Most relevant to the proposed 
research project, Syrian Golden hamsters have been utilized in a considerable 
number of research studies involving members of the Flavivirus genus. The 
rodent model has been employed in studies involving ZIKV, YFV, DENV, Modoc 
virus (MODV), and West Nile Virus (WNV) [104-107]. Two recent studies 
involving Syrian golden hamsters have generated contradictory findings 
regarding the susceptibility of the animal model to ZIKV infection. Ragan et al. 
evaluated 17 different North American species representing birds, rodents, 
amphibians, reptiles, and livestock to ZIKV infection. The study evaluated each 
animals permissiveness to the PRVACB59 and FSS13025 (2010 Cambodian 
isolate; Asian lineage) ZIKV isolates and replication by testing for viral RNA with 
RT-qPCR and tittering infectious virus levels with Plaque forming unit (PFU) 
assay in sera and kidney, liver, and spleen tissues. Seroconversion of the 
selected animals was also evaluated through plaque reduction neutralization 
tests. The results of the study indicated that all 6 of the Syrian golden hamsters 
employed in the study were not susceptible to ZIKV infection. The researchers 
were unable to detect infectious virus, viral RNA, or antibodies in any of the 
collected Syrian golden hamsters [108]. However, Miller et al.’s discoveries in a 
study evaluating the potential of Syrian golden hamsters and Strain 13 Guinea 
pigs as potential ZIKV animal models contradict Ragan et al.’s findings. The 




(Senegal 1984 isolate; African lineage) and CPC-740 (Phillipines 2012; Asian 
lineage) ZIKV isolates through subcutaneous (SQ) and intraperitoneal (IP) 
inoculations. Susceptibility to ZIKV infection was evaluated by daily signs of 
disease monitoring, histopathological analysis on collected organs, viral tittering 
in sera by PFU assays, and ZIKV reactive antibody levels with plaque reduction 
neutralization test assays. High levels of neutralizing antibodies were detected in 
animals challenged with both ZIKV isolates regardless of inoculation route. 
However, viremia was only detected in the sera samples of hamsters inoculated 
IP with the ArD41525 isolate. The results of Miller et al.’s work provides 
supporting evidence for the potential of Syrian golden hamsters as an 
immunocompetent ZIKV disease model, as well as providing more evidence 
regarding the significant differences between the virulence of ZIKV’s African and 
Asian lineages [96].  
Between the three selected animal models, Jamaican fruit bats are the 
most unique animal model involved in the current study. The initial interest in 
evaluating bats as a novel ZIKV model originated from a research study from 
1955 involving experimental ZIKV infections of the little brown bat (Myotus 
lucifugus). Reagan et al. carried out 5 different routes of inoculation 
(intraperitoneal, intrarectal, intradermal, intracerebral, and intranasal) to 
extensively test the susceptibility of the small cave bat to ZIKV infection. The 
results indicated that small cave bats are susceptible to the multi-passaged 




researchers also observed severe neurological manifestations in the bats on 
days 4-7 post infection [109].  
Bats are attractive as potential animal in viral research because of the 
well-established role of bats as the reservoir host for a wide variety of families 
and genera of viruses [110, 111]. A reservoir host is distinguished from a host 
that experiences disease by the animal’s capacity to become persistently 
infected and transmit the microbe with little to no clinical disease manifestations. 
Within the flavivirus genus alone, 21 different members have been isolated from 
one or more species of bats [110, 112-115]. Relevant human pathogens of the 
21 flavivirus species include St. Louis encephalitis virus (SLEV), WNV, DENV, 
JEV, YFV, and ZIKV.  As well, serological evidence from multiple survey studies 
has also demonstrated the presence of DENV, SLEV, WNV, and YFV reactive 
antibodies in sera from Jamaican fruit bats [114, 116]. A recent study from 
Malmlov et al. supported the findings of ZIKV susceptibility from the serological 
surveys in wild bats by conducting an in vivo challenge of captive Jamaican fruit 
bats to the PRVABC59 ZIKV isolate. Although the inoculated bats did not present 
with any clinical manifestations during the study, viral RNA was detected through 
probe-based RT-qPCR in the brain tissue of one bat at day 2 post inoculation 
and the urine of two bats at days 3 and 5 post inoculation. Moderate levels of 
ZIKV reactive antibodies relative to the human convalescent control (Bat: 
3,200|Human: >12,800) were also detected in the serum of all of the bats at their 
selected euthanasia time points during the 28-day research timeline. 




the infected bats indicated that lesions likely induced by ZIKV infection were 
present in the testes, brain, and salivary glands of the bats [117].  Reagan et al.’s 
and Malmlov et al.’s findings alone provide a solid reasoning for investigating 
ZIKV susceptibility in bats, but the evidence from countless studies regarding the 
association between bats and multiple flaviviruses reinforces the support for the 
Jamaican fruit bat’s potential as a viable immunocompetent ZIKV animal model. 
In contrast to Syrian golden hamsters and Jamaican fruit bats, deer mice 
only have minimal use in previous research related to members of the Flavivirus 
genus. Only one study involving deer mice and ZIKV has been published to date. 
The aforementioned Ragan et al. study evaluated the potential of 17 North 
American species to serve as ZIKV hosts. This included an investigation into the 
susceptibility of deer mice to ZIKV. Ragan et al. found that none of the evaluated 
deer mice (n=5) were susceptible to ZIKV infection when assessed using virus 
isolation and PCR [108]. Although these findings are somewhat disconcerting to 
the goals of the current study, confirming or providing evidence against the 
findings of the previous study adds to the weight to the findings yielded in the 
current study. Aside from Ragan et al.’s work, deer mouse involvement in 
previous viral research has primarily examined the rodent’s role as a reservoir 
host for MODV and Sin Nombre (Orthohantavirus) [118-120]. Understanding how 
a reservoir host can become infected without the manifestation of disease 
provides an interesting research avenue aimed at aiding in the development of 
therapeutic treatments for controlling the same infection in humans. The current 




that our findings will allow for the comparison of ZIKV’s virulence and host cell 
immune response between a pathogenic model and a reservoir host (non-
pathogenic) model.  
Specific Aims 
The lack of an adequate immunocompetent animal model for ZIKV 
research poses a considerable concern for current research regarding the virus 
and for the design and testing of efficacious vaccines to protect against future 
ZIKV outbreaks. Along with supplementing the current understanding of ZIKV’s 
effects across species, the current study looks to provide the pilot data for the 
potential development of an immunocompetent ZIKV vaccine model. As well, 
expression levels of genes associated with the Type I IFN response will be 
compared between control and ZIKV treated cell lines to elucidate novel 
information regarding the interaction and suppression of ZIKV with one of the 
primary innate anti-viral immune response pathways. In doing so, we hope to 
provide information that will aid in the development of therapeutic treatments 
against ZIKV to mediate the burden of the viral outbreaks until a FDA-approved 
vaccine is commercially available. 
 
A1  Determine the susceptibility of primary kidney cell, pulmonary cell 
(lung), and hepatocyte (liver) to ZIKV by evaluating cell pellet 
samples with endpoint PCR for ZIKV RNA to determine 
susceptibility.  
 
H1  We hypothesize that primary cell cultures derived from the 
Jamaican fruit bat and Syrian golden hamster will have detectable 
levels of ZIKV RNA in all of the 72 hour post infection timepoint 
samples. Deer mouse cell culture samples will not have detectable 





A2  Determine the permissiveness of established primary cell lines to 
ZIKV replication by evaluating cell culture suspension samples with 
endpoint PCR for ZIKV RNA to determine permissiveness to ZIKV 
replication. The titer of infectious virus in ZIKV treated cell culture 
suspension will also be determined using the Reed Muench viral 
titer assay method.  
 
H2 We hypothesize that primary cell lines from the Jamaican fruit bat 
and Syrian golden hamster will have detectable levels of ZIKV RNA 
in all of the 72 hour timepoint samples and viral titer will be present 
in liver and lung derived cell cultures from both animals. Deer 
mouse cell culture samples will not have detectable levels of ZIKV 
RNA or infectious virus in 72 hour  viral treated suspension 
samples.  
 
A3  Genes associated with the Type I IFN response will be examined in 
each cell line. Transcript levels of STAT1, JAK1, ISG15 and Oas1b 
will be determined via semi-quantitative PCR to give insight into the 
expression and possible viral suppression of the selected genes in 
response to ZIKV infection.  
 
H3 We hypothesize that JAK1 and STAT1 expression will significantly 
increase in samples with ZIKV RNA and infectious virus present in 
cell culture suspension. ISG15 and Oas1b will have little to no 
increases in gene transcript expression in samples with ZIKV RNA 
and infectious virus present in cell culture suspension.  
 
Chapter Summary 
Zika virus has become a major concern regarding public health due to its 
exceptional rate of spread, novel modes of transmission, association with severe 
neurological symptoms and lack of an available vaccine or therapeutic treatment. 
Although ZIKV was first isolated over 70 years ago, the lack of major outbreaks 
until 2007 has led to a significant deficiency in the understanding of ZIKV’s 
characteristics and pathology in humans as well as across a diversity of species 
[24]. It is likely that ZIKV will continue to spread and become endemic in regions 




primary vector, Aedes species mosquitoes [45, 46]. Therefore, it is imperative 
that current research works towards resolving the lack of information regarding 
ZIKV and developing a safe and efficacious vaccine against the virus. The lack of 
an adequate immunocompetent animal model for ZIKV research poses a 
considerable concern for current research regarding the virus and for the design 
and testing of efficacious vaccines to protect against future ZIKV outbreaks. 
Along with supplementing the current understanding of ZIKV’s virus host-
interaction across species, the current study looks to provide the pilot data for the 
potential development of an immunocompetent ZIKV vaccine model. As well, 
components of the Type I IFN response, will be investigated in susceptible cell 
lines to elucidate novel information regarding the interaction and suppression of 
ZIKV with one of the primary innate anti-viral immune response pathways. In 
doing so, we hope to provide information that will aid in the development of 
therapeutic treatments against ZIKV to alleviate the burden of the virus until a 















CHAPTER II  
METHODOLOGY 
Purpose of the Study  
 The purpose of the current study aims to provide data and insight into two 
critical areas of Zika virus (ZIKV) research. As a primary objective, the current 
study looks to provide the pilot data required to warrant further research into the 
three selected mammalian species as novel immunocompetent ZIKV animal 
models. Establishing a novel immunocompetent animal model would aid future 
research involving development and testing of vaccines and therapeutic 
treatments against ZIKV. Along with providing pilot data, we seek to provide 
insight into virus-host interaction of ZIKV with three mammalian species as a 
secondary objective. Here, we investigate ZIKV susceptibility and host cell’s 
antiviral response in primary cell lines derived from three mammalian species. 
Results from this study will benefit the understanding of ZIKV’s virus-host 
interaction across species. The current study utilizes primary cell culture from 
three novel animal models, Ribonucleic acid (RNA) extraction, complementary 
Deoxyribonucleic acid (cDNA) synthesis, standard-endpoint Polymerase Chain 
Reaction (PCR), and semi-quantitative PCR techniques to investigate the 






Establishing Primary Cell Lines 
In order to establish the primary cell lines necessary for the present 
research, three different tissues, liver, lung and kidney, were collected from deer 
mice (Peromyscus maniculatus), Syrian golden hamsters (Mesocricetus auratus) 
and  Jamaican fruit bats (Artibeus jamaicensis) for the establishment the primary 
cell cultures through accepted standard operating procedures (SOP). Deer mice 
and hamster tissues were collected from males of 6-9 weeks of age at the time of 
necropsy. Due to the lack of a standardized method for determining the age of 
bats, the only selection parameter for the Jamaican fruit bats was ensuring that 
the subjects were males. Three sets of each primary cell culture were derived 
from three different male bats and deer mice (18 total primary cell cultures) to 
represent biological replicates. Due to initial issues with establishing all of the cell 
types from a single animal, the primary cell cultures utilized in the experimental 
infection are not all drawn from the same animal. Continuous problems with 
establishing viable primary kidney and liver cultures from the Syrian golden 
hamsters resulted in only establishing three sets of primary lung cell cultures 
from the third animal model. Although the lack of primary cell types from all three 
tissues in Syrian golden hamsters significantly limits the ability to compare 
between all three animal models, it is still relevant to evaluate the established 
cultures in regard to the goal of the current study. In summation, 3 sets of 7 
different primary cell lines (21 total primary cell cultures) were established the 
current study. For all cell types, cells were passage using a standard 1:10 split 




spun at 300 x g. Table 1 provides a visual representation of the established 
cultures.  
Animals were humanely euthanized per the deer mouse IACUC protocol 
(1109B-AH-DM-14, Hamster Animal Research Facility IACUC holding protocol, 
Bat Animal Research Facility IAUCAC colony protocol) and no work was done on 
live animals. Prior to use in the current study, animals were cared for and housed 
by the University of Northern Colorado’s Animal Research Facility Staff as 
outlined in the IACUC protocols. In brief, the humane euthanasia of the animals 
was carried out through respiratory administration of isoflurane (3% to effect) 
followed by cervical dislocation and thoracotomy to ensure death prior to tissue 
collection. Please see the appendix for more information regarding the IACUC 
protocols. Kidney and lung tissue were collected in 100 mm TC dishes with 
appropriate collection media, and the liver tissue was perfused with perfusion 
buffers  using a modified two step collagenase perfusion method (outlined below) 
prior to collection. All of the primary cell lines were initially seeded in a T-25 or T-
75 tissue culture flask depending on the resulting cell yield. Initial cultures were 
passaged at least once after reaching 90-95% confluency prior to use in the 
experimental infections.  
Primary Pulmonary Cell Culture 
Primary Pulmonary cell (PC) cultures were established following a 
modified Sobczak, et al. Pulmonary Microvascular Endothelial cell isolation with a 
collagenase and elastase enzymatic digestion protocol [121]. Prior to conducting 




allowed to dry for at least two hours prior to use. If the flasks were coated the day 
before, they were allowed to dry for two hours and then they were stored at 4 oC 
overnight. The coated flask stored in the refrigerator were warmed to room 
temperature prior to being utilized for cell culture. During each necropsy, excised 
lung tissue was collected in 15 ml of ice-cold Dulbecco’s Modified Eagle Medium 
(DMEM) initially and then transferred into a 100 mm TC dish. The lung tissue 
was minced into fine pieces using sterile scissors and then collected in 15ml 
conical containing 15ml of a collagenase and elastase enzyme mixture 
suspended in DMEM. The lung tissue was allowed to digest in the enzyme 
cocktail for 45 minutes on a rotator at 37oC. Once the enzymatic digestion was 
complete, the digested tissue suspension was aspirated into a 30 ml syringe 
through a 20-gauge needle. The suspension was expressed from the 30 ml 
syringe and collected back into the 15 ml conical. The previous step was 
performed at least twelve times on each suspension to break up any clumps to 
ensure a single cell suspension. The subsequent single cell suspension was 
pipetted into a 10 ml pipette and the leftover tissue chunks were allowed to settle 
prior to slowly dispensing the resulting supernatant back into the 15 ml conical 
tube. The purpose of the previous step was to remove any leftover chunks that 
were too large to be digested by the enzyme cocktail. In order to disrupt any 
remaining enzyme activity, the single cell suspension was mixed with 15 ml of 
isolation media (20% FBS DMEM w/ 1x Penicillin/Streptromycin) and collected in 
a sterile 50 ml conical tube. Cells in the suspension were pelleted down by 




decanted. The cells were suspended and washed in 3 ml of 0.1% Bovine Serum 
Albumin/Phosphate-buffered saline solution, and centrifuged at 400 x g. 
Supernatant was decanted again and the cell pellet was re-suspended in 11 ml 
of the  Vasculife with the EnGS-Mv life factors kit supplemented with 1x 
pen/strep/fungizone. The 11 ml of  PC cell suspension was seeded into a pre-
coated T-75 flask and placed in an incubator set at 37oC with 5% CO2. A cell 
count was not performed on the cell suspension product, because all of the 
extract PC cells were pooled and used to seed single T-75.   
New PC cultures were allowed to incubator for one full day before media 
was exchanged. All of the media was changed on the first day post inoculation 
and then half of the media was exchanged every 2-3 days. Once the PC cultures 
reached 90-95% confluency, they were regularly split at a 1:10 ratio. During the 
third or fourth passage, PC cell suspensions were used to seed two T-75 flasks. 
The first culture was used for the experimental infections and the second culture 
was passaged and frozen back in liquid nitrogen for future use. PC cells would 
be frozen back in four 1.5 ml cryovials suspended in freeze medium (10% 
dimethylsulfoxide/ 20% FBS DMEM). The PC cultures prepared for the 
experimental infections were allowed to grow to 90-95% before being split at a 
1:20 ratio into 10 T-12.5 flasks. The final volume of the T-12.5 flasks were 
brought up to 3 ml with Vasculife media and the cultures were allowed to grow 






Primary Kidney Cell Cultures 
Primary kidney cell were established using a protocol previously 
developed by the Hawkinson laboratory. Excised kidneys were collected under a 
BSL2 Biosafety cabinet in a 100 mm tissue culture dish with 10 ml of 1x 
Dulbecco’s phosphate buffered-saline (DPBS) and minced into small pieces 
using a #11 scalpel. The 1x DPBS and kidney chunk solution was transferred 
into a 50 ml conical to allow for the kidney pieces to settle at the bottom. The 
DPBS was aspirated from the 50 ml conical tube and the kidney pieces were 
transferred into a 50 ml sterile pleated flask containing a stir bar and 12 ml of 
0.25% trypsin.  The kidney pieces were enzymatically and mechanically digested 
for 15 with the trypsin and rotating stir bar on a stir plate. The pleated flask with 
the trypsin and kidney piece suspension was placed on a stir plate and allowed 
to mechanically and enzymatically digest for 15 minutes at 25 oC. After 
completing the digestion step, the resulting suspension was transferred back into 
the original 50 ml conical tube. The undigested kidney cell chunks were allowed 
to settle to the bottom before being transferred to a new 50 ml conical tube 
containing 20 ml of 10% FBS DMEM. The addition of the 10% FBS DMEM to the 
cell suspension was important to inhibit any remaining trypsin activity. After 
neutralizing the trypsin, the kidney cells were pelleted down by centrifugation at 
400 x g for 5 minutes. The resulting supernatant was decanted and the cell pellet 
was re-suspended in 10 ml of 10% DMEM before being centrifuged again at 400 
x g for 5 minutes. The previous step was repeated again with another 10 ml of 




the resulting pellet was re-suspended in 10 ml of 10% FBS DMEM and seeded 
into a T-25 flask. Initially, kidney cell suspensions were counted and seeded at 
the recommended 0.7x106 cells/ml seed density, but the yielded kidney cell 
suspensions were eventually pooled into a single T-25 after losing multiple 
kidney cell cultures due to low seeding densities. The volume of the T-25 was 
brought up to 5 ml with 10% FBS Dulbecco’s Modified Eagle Medium with 1x 
pen/strep/fungizone and incubated at 37oC with 5% CO2. After 24 hours, all of 
the media was exchanged with fresh 10% FBS DMEM. Half of the media was 
exchanged every 2-3 days until the cultures were ready to be split into the T-25 
flasks for experimental infections. 
Primary Hepatocyte Cultures 
Hepatocytes were isolated using a modified two-step collagenase 
perfusion method as outlined in Li, et al. for the isolation of adult mouse 
hepatocytes [122]. Ca+2 and Collagenase Type I (Worthington Biochemical) 
concentrations (5 mM, and 200 U/mL, respectively) of perfusion buffer II, FBS 
and dexamethazone concentrations (20% and 1 µM, respectively) in the 
hepatocyte attachment media, and centrifugation speeds (50-100 x g) were 
altered from the selected protocol in order to optimize hepatocyte cell yield and 
viability [123-128]. Prior to conducting each necropsy, two T-75 flasks were 
coated with 4 ml of a 0.1 mg/ml Poly-D-lysine solution (mol wt 70,000-150,000) 
and allowed to dry for at least two hours prior to use. If the flasks were coated the 
day before, they were allowed to dry for two hours and then they were stored at 4 




room temperature prior to being utilized for cell culture. In order to perform the 
perfusion, a peristaltic pump fitted with 6.3 mm medical tubing was used to 
perfuse the two buffers through the liver. A 36 ½ gauge needle was attached to 
one end of the pump’s tubing and the other end of the tubing was placed in the 
corresponding buffer at each procedural step. Both of the required perfusion 
buffers were made up to 24 hours prior to hepatocyte isolation and warmed up in 
a water bath to 43 oC for at least 30 minutes before the procedure. The 43 oC 
temperature setting was employed to achieve the optimal temperature output of 
the perfusion buffers after flowing through the peristaltic pump tubing. It is 
important to note that the collagenase can only be added to perfusion buffer II 
(Hanks Balanced Salt Solution with Ca+2 /Mg+2  and 25 mM HEPES, 0.72% 
Bovine Serum Albumin and increased Ca2+ concentration of  3 mM) 30 minutes 
prior to conducting the procedure. The enzymatic activity of collagenase will 
begin to decrease after 30 minutes at 37 oC. Once the liver was exposed, the left 
and right lobes of the liver were gently lifted with sterile forceps and the intestines 
are pushed to the right side of the animal to expose the hepatic portal vein and 
inferior vena cava. A 36 ½ gauge needle was inserted into the hepatic portal vein 
and the peristaltic pump was turned on with a flow rate of 5 ml per minute. The 
inferior vena was severed to allow for the perfusion buffers to effuse after 
circulating through the liver. The liver was initially perfused with perfusion buffer I 
(Hank’s Balanced salt solution w/out Ca+2 and Mg+2 and 0.5 mM EDTA) for ten 
minutes. After 2 to 3 minutes, the flow rate was increased from the 5 ml per 




procedure. Observing a color change of the liver from red to a light yellow and an 
marked ballooning effect of the left and right lateral lobes during the initial 
perfusion indicates a successful start to the perfusion. The first step of the 
perfusion method with perfusion buffer I was used to washout and remove any 
blood and calcium present in the liver. The purpose of removing the calcium from 
the tissue is to disrupt any calcium dependent adhesion factors that are 
maintaining intercellular connections in the liver [129, 130]. After completing the 
first perfusion, the tubing was transferred to the perfusion buffer II w/ collagenase 
reservoir and the buffer perfused the liver for an additional 10 minutes at a 
flowrate of 10 mls per minute. Perfusing the liver with the collagenase buffer 
enzymatically cleaves any remaining intercellular connections between 
hepatocytes as well as other non-parenchymal cells. Upon completion of second 
perfusion, the liver was carefully excised from the animal and collected in a 100 
mm TC dish with 20 ml of perfusion buffer II w/ collagenase. To release the 
hepatocytes from the digested liver, the Glisson’s capsule was gently pulled 
apart using sterile forceps and then the liver was shaken using one of the forceps 
to dissociate the hepatocytes into the suspension. Figure 2.1 shows an image of 
the isolated hepatic portal vein and vena cava, color changes resulting from 
successful perfusion, and resulting liver cell suspension after excision and 
removal of the Glisson’s capsule. The resulting suspension was filtered through a 
100 µM pore cell strainer into 50 ml conical tube to remove any connective tissue 
or undigested tissue fragments. During the bat hepatocyte procedures, the 




of cells in resulting from a relatively larger organ. The collagenase enzymatic 
activity was disrupted by adding 20 ml of hepatocyte wash media (7% Williams E 
medium with 1x Penicillin/Streptromycin/Insulin-Transferrin-Selenium/Sodium 
pyruvate) to the 50 ml conical tubes. The filtered suspension was centrifuged at 
50 x g for 3 minutes at 22 oC. It is very important to keep the centrifugation speed 
of hepatocytes below 100 x g. Previous research has shown that going above 
100 x g when centrifuging hepatocytes can significantly damage the cells and will 
result in a substantial loss of hepatocyte yield and viability [123, 124, 131]. The 
supernatant from the centrifuged tube was aspirated with a 25 ml serological 
pipette and the previous wash step was repeated twice with 20 ml of hepatocyte 
wash media (three washes total). The resulting cell pellet was brought up in 10 
ml of hepatocyte attachment media (20% FBS William’s Complete media with 1x 
penicillin/streptomycin/fungizone/1x Insulin-Transferrin-Selenium). Hepatocytes 
yielded from the procedure were split evenly (5 ml in each) between two T-75 
Poly-D-lysine coated culture flask. The total volume of the T-75 was brought up 
to 11 ml with hepatocyte attachment media and the flaks were placed in the 
incubator for 24 hours. In the deer mice hepatocyte cultures, the attachment 
media is switched to a 1:1 mixture of 5% FBS F-12K (w/ ½ x 
Penicillin/Streptromycin/Amphotericin) and Vasculife EnGS-Mv life factor media 
after 24 hours. Conversely, Jamaican fruit bat hepatocytes were switched to a 
formulation of 10% FBS F-12K only after the 24 hours attachment period. Half of 
the media exchanged every 2-3 days until the cultures were ready to be split into 




      
Figure 2.1: Step by step images of the two-step perfusion method for the 
isolation of primary hepatocytes. Image (A) The isolated hepatic portal vein 
and inferior vena cava.  (B) The insertion of the perfusion needle into the hepatic 
portal vein. (C) The initial color change/blanching caused by successfully 
perfusion of buffer I the liver. (D) The complete color change/blanching and 
ballooning of the liver caused by both perfusion buffers. (E) The excised liver 
after perfusion in a 100 mm TC dish. (F) The single cell suspension generated by 




In preparation for the experimental infections, stock PRVABC59 ZIKV P4 
(Passage 4) was obtained from Dr. Tony Schountz’s lab at Colorado State 
University. This stock came from the Centers for Disease Control and Prevention 
in Fort Collins. Virus was passaged in Vero cell culture in order to provide 




was collected on days 3, 6 and 7 post-infection and viral titer of the resulting 
stock was measured using the Reed-Muench method in 96-well TC plates. Stock 
virus collected on day 3 during the Vero cell infections was used to conduct the 
subsequent experimental infections in the primary cell lines. The viral titer of PR 
ZIKV P5 stock day 3 was measured three times using the Reed-Muench method 
and the results indicated an average viral titer of 1x106.65 infectious virions/ml.  
Experimental Infections 
As noted above, hepatocyte and PC cell cultures were passaged into 10 
T-12.5 flasks and primary kidney cells were passaged into 10 T-25 flasks prior to 
experimental infection. Kidney cells were passaged into larger flasks because of 
issues with pelleting the cells that were observed during trial runs of the sample 
collection method. The cells were incubated at 37oC with 5% CO2  and media 
was exchanged every two days until the cultures were ready for the experimental 
infections. Once the flasks were 85-90% confluent, they were separated into two 
different treatment groups; 5 flasks for Mock (-K) infections and 5 flasks for the 
experimental ZIKV infections. After the 10 primary cell cultures for each tissue 
type reached 85-90% confluency, the culture media was removed, and cells were 
washed using sterile 1X Dulbecco’s phosphate buffered saline.  Five flasks from 
each tissue type were used for ZIKV treatments. Each well was experimentally 
infected with a 1:10 dilution of Stock PRVABC59 ZIKV isolate suspended in the 
corresponding maintenance media (2 % fetal bovine serum (FBS) DMEM, 5% 
FBS Vasculife, or 5% FBS F-12K). Flasks for each tissue type were treated as 




The cells were rocked at 25oC for 1 hour to allow for viral adsorption. After 
completion of the 1-hour adsorption period, ZIKV and mock media were removed 
and replaced with 3 ml of maintenance cell culture media.  
Sample Collection 
Flasks containing the mock and ZIKV infected primary cell cultures were 
trypsinized (0.025% Trypsin w/ EDTA) for 10 minutes at 37oC and then 
mechanically dissociated with a cell scraper at 12, 24, 48, and 72 hours post 
infection (hpi). Cell culture supernatant was also collected and frozen back at -4 
oC  in 15 ml conical during the 72 hpi collection timepoint for future detection of 
viral RNA in the culture suspension. Following mechanical dissociation, cells 
were washed and collected in a 15-mL conical tube with 10% FBS DMEM (PC 
and kidney) or hepatocyte wash media (hepatocytes). The collected cell 
suspension was pelleted down at 500 x g for 10 minutes and the supernatant 
was decanted. After the initial decanting, the cells were subsequently ran at 500 
x g for 3 minutes to help pull the remaining media to the bottom of the conical 
tube. Any remaining cell culture media was removed via a micropipette and 
discarded to avoid any disruption of the RNA isolation process by media 
components. The collected cell pellets were frozen back at -4 oC until cellular 
RNA was extracted from the samples.  
Ribonucleic Acid Extraction 
and Detection of Viral 
Ribonucleic Acid 
 
 Viral RNA was extracted from supernatant samples collected at the 72 




E.Z.N.A viral RNA kits. The extracted viral RNA was reverse transcribed into 
complementary DNA (cDNA) using the EPISCRIPT RNase H- RT kit with ZIKV 
specific primers designed to amplify a conserved region of the ZIKV E protein 
sequence. Prepared samples were run on a modified version of the RT 
thermocycler program (optimized by Tyler Sherman). Sample mix 1 (template 
and primers) was run at 94 oC for 1 minute, immediately placed on ice for 3 
minutes, gently mixed with the RT master mix, and finally ran at 45 oC for 1hr and 
30 minutes. The subsequent cDNA samples were employed in end point 
Polymerase chain reaction (PCR) using the Quantabio Accustart II PCR 
supermix with the same primer set used for cDNA synthesis. 5 ul of cDNA 
template mixed with 20 ul of PCR MM (following Accustart II PCR supermix 
protocol) in DNase and RNase free PCR tubes. Mixed samples were run on the 
thermocycler program, ZIKV. The ZIKV program was optimized over multiple 
trials for effective detection of viral RNA with the Accustart II Supermix kit. The 
resulting PCR products were assessed for the presence of the viral RNA 
sequences via gel electrophoresis on a 2% agarose gel containing Ethidium 
Bromide. The PCR products were mixed with 5 ul of loading dye and loaded into 
the predetermined agarose gel well. Two ladders were added to the outside wells 
flanking the PCR product samples and the gel was run for 40 minutes at 110 
volts, A sample with a band at the expected 362 bp PCR product size was 






Viral Titer Assay 
Cell culture suspension from ZIKV treated 72 hour timepoint samples were 
tittered following the widely accepted Reed Muench viral titer method. Vero E6 
cells were cultured in a 96 well cell culture plate and allowed to grow to 85-95% 
confluency at 37 oC with 5% CO2 prior to conducting the viral titer assay. ZIKV 
treated 72 hour timepoint sample suspensions were serially diluted at a 1/10 ratio 
(10-1 to 10-8) with 2% FBS DMEM (Vero E6 media) in autoclaved eppendorf 
tubes. Serially dilute suspensions (100 ul) were aliquoted in to the 96 well plate in 
descending order and incubated at 37 oC with 5% CO2 for 30 minutes to allow for 
an adsorption period. A positive control of PR ZIKV stock virus suspension and a 
negative control of cell culture suspension from the corresponding control 72 
timepoint sample were also aliquoted into the first and last rows of the 96 well 
plate. After completing the adsorption step, 150 ul of 2% FBS DMEM was added 
to each well before placing the plates back into the incubator. Plates were 
allowed to incubate for 9 days before being read out using the Reed Muench viral 
titer calculation method. Viral titers were calculated as tissue culture infectious 
dose 50 (TCID50) values using the appearance of cytopathic effect (CPE) in 72 
hour timepoint sample wells as a positive result. See figure 2.2 for a visual 
example of the marked difference between a well positive for CPE and a non-





         
Figure 2.2: A comparison of a non-infected Vero E-6 well with a ZIKV 
infected well.  CPE is evident in the ZIKV infected well (right) marked by the 
presence of clearing in the cell monolayer, increased amounts of dead cells 
floating in suspension (dark rounded cells), and abnormal morphology of 
remaining adherent cells.  
 
Cellular Ribonucleic Acid Extraction and 
Examination of Type I Interferon 
Associated Genes 
 
  Omega E.Z.N.A Total RNA kits and corresponding kit protocol were used 
to extract cellular RNA from the collected timepoint cell pellets. Viral RNA was 
also collected from ZIKV treated timepoint samples by re-suspending the cell 
pellet in 700 ul of the RTK lysis buffer (Total RNA kit lysis buffer) and splitting the 
sample evenly into two 350 ul samples. From this point, RNA extraction of both 
sample types (viral and cellular) was carried out following the protocol outlined in 
the respective RNA isolation kits without any further alterations. Extracted RNA 
samples were analyzed for genomic DNA, lysis buffer, and unwanted cellular 
component contamination with a Thermo scientific Nanodrop 2000 
Spectrophotometer. Contaminated samples, indicated by a 260/280 ratio value 




lower than 1.9 were cleaned with a sodium acetate clean up protocol (provided 
by Dr. Karen Gomez’s lab). Cleaned RNA samples were retested on the 
Nanodrop to ensure that the contamination issue had been resolved.  
Nanodrop results also gave a relative concentration of RNA within each 
samples, which was used to calculate the volume of RNA sample added in the 
subsequent DNase treatment step. The volume of RNA sample added to each 
DNase reaction was calculated to yield the Promega RQ1 RNase-free DNase 
kit’s recommended RNA concentration of 2ug per reaction. Mixed DNase 
reaction samples were aliquoted following the kits protocol with no alterations. 
Samples were placed on the thermocycler and ran at 37 oC for 30 minutes, 
placed on ice while adding 1ul of DNase STOP buffer, and finally ran at 65 oC for 
10 minutes to end DNase enzyme activity. DNase treated samples were used for 
complementary DNA (cDNA) synthesis within 30 minutes of completing the 
treatment step. The immediate use of the treated RNA for cDNA was carried out 
to decrease the degradation and loss of target cellular RNA from a freeze/thaw 
cycle.  
At this point in the PCR analysis, viral RNA and cellular RNA samples 
diverged in their reaction kits and applications. Extracted viral RNA samples from 
the 72 hour ZIKV treated cell pellets underwent cDNA synthesis using the same 
EPISCRIPT RT kit and protocol outlined for the viral RNA suspension samples. 
The resulting cell pellet cDNA samples were evaluated for the presence of ZIKV 
RNA using the same ZIKV E primers, Accustart II PCR supermix kit with 5 ul of 




suspension samples. Resulting PCR products were evaluated for the presence of 
ZIKV RNA in the same manner as the suspension with no alterations (2% 
agarose gel w/ Ethidium Bromide ; 110 volts for 40 minutes).  
DNase treated cellular RNA samples were reverse transcribed into cDNA 
using a qScript cDNA supermix kit. Calculations for determining the volume of 
DNase treated RNA added in for cDNA synthesis of each sample was based on 
yielding a £ 1ug concentration of total cellular RNA per reaction. Synthesized 
cellular cDNA from 72 hour timepoint samples were evaluated for the presence 
and expression of Type I IFN associated gene transcripts through Semi-
quantitative PCR techniques. PCR was carried out on the 72 hour cDNA sample 
with the Accustart II PCR supermix kit. PCR MM was aliquoted following the 
Accustart supermix protocol (primer conc. at 200 nm), mixed thoroughly, and 
then dispensed into each tube with a Thermofisher scientific electronic 
multichannel equalizer pipette. A standard of 3 ul of cDNA from the 72 hour 
timepoint samples (both control and treated) was mixed into the corresponding 
PCR tube prior to being ran on the ImmuneGene program. The 
annealing/elongation step temperatures were altered from the standard 60 oC for 
b-actin and the AJ ISG15 (bat) primer set sample runs. Although B-actin, JAK1 
and STAT1 levels were evaluated for the 72 hour timepoint samples from all 
three animal, working primer sets for ISG15 and Oas1b were not available for all 
three species. ISG15 was only evaluated in deer mice and Jamaican fruit bats, 




samples. Resulting PCR products were run on a 2% agarose gel with EtBr in the 
same manner as the viral RNA suspension and cell pellet samples.  
Images were taken of the visualized PCR products and uploaded for band 
density analysis using the image analysis software, FIJI.  
 
Table 2.1: Thermocycler programs for PCR analysis. 
Thermocycler Programs for PCR Analysis 
Program ZIKV Immune Genes 
Thermocycler Bio-Rad MJ mini Thermal cycler Bio-Rad T100 Thermal cycler 
1: Initial denaturing 
step 94
 oC for 5 minutes 94 oC for 3 minutes 
2: Cycle denaturing 
step 94
 oC for 1 minute 94 oC for 30 seconds 
3: Annealing step 59 oC for 30 seconds 
B-actin: 59 oC 
JAK1: 60 oC 
STAT1: 60 oC 
ISG15- AJ: 55 oC, DM: 60 
oC 
Oas1b:  60 oC 
For 1 
minute 
4: Elongation step 72 oC for 30 seconds 
5:Repeat steps 2 -4 # 
of times 35x 35x 
6: Hold at 4 oC ¥ ¥ 
 
Note: A visual comparison of the two thermocycler programs used with the 
Accustart II PCR supermix kit to test samples for the presence of ZIKV RNA and 
Type I IFN related immune genes (JAK1, STAT1, ISG15, and OAS1b with b-actin 
as the reference gene). The annealing and elongation step of the immune gene 
program are combined into a single step. Optimization trials indicated that 
keeping the reaction at the optimal primer melt temp generates a cleaner PCR 









Table 2.2: A list of the primer sequences and PCR product sizes for all 
eight of the primer sets. 
 



























































































AGCATGGACT 125 60 




























Note: The forward and reverse sequence optimized melting temp, and expected 
base pair size for each of the selected primer sets is displayed in the table. 
Differing expected PCR product sizes are listed with an acronym corresponding 
to the species producing the different product size (AJ- bat, DM- deer mouse, 
HAM- hamster). The PCR product size for ISG15 for hamster samples and 
Oas1b for bat samples are not listed because working primers for the genes in 











The PCR product of each of the selected genes for a single tissue type of 
each animal were ran in a set of 4 or 5 neighboring wells to observe the 
expression of immune genes within a single primary cell type from one animal. 
Control and ZIKV treated samples were also ran in parallel on the same row of a 
gel to allow for the semi-quantitative analysis of the PCR product band density 
between the different treatments. Gel images were taken on the Hawkinson lab 
U.V. lightbox and then converted to a black and white image. Utilizing the image 
analysis software FIJI, uploaded images of the immune gene PCR product gels 
were formatted for band density analysis by converting the image to an 8-bit 
format, inverting the black and white gradient, and adjusting the brightness and 
contrast to increase the clarity of the image. The black and white gradients of the 
image are inverted to allow for FIJI to quantify the relative levels of PCR product 
by calculating the density of the band compared to either the light background or 
another PCR product band. See figure 2.3 for a comparison between the original 










Figure 2.3: A comparison between the original immune gene PCR products 
gel image from bat 7’s hepatocyte cell pellet RNA and the FIJI converted 
image . The left image is the original and the right image is the FIJI converted 
image. The first four bands (L to R) represent B-actin, JAK1, STAT1 and ISG15 
for Bat 7 hepatocyte 72 hour control sample. The second set of bands represent 
the same genes for Bat 7 hepatocytes’ 72 hour ZIKV treated sample. 
 
PCR product band densities for the selected genes were calculated by 
conducting the Gel Analyzer program in FIJI. The Gel analyzer program is a four-
step protocol that was carried out by highlighting the first band of interest and 
designating it as the first lane (command + 1). After the first lane was selected, 
the highlighted rectangle of the first band was dragged to the region of the 
second band of interest. The second band of interest was designated as the 
second lane (command + 2). Once both lanes were selected, the density of each 
band was visualized by plotting the lanes (command + 3).  The plotted lanes 
were displayed as two different peaks in the same order as they were selected 
(i.e. lane 1 was the top peak and lane two was the bottom peak). See figure 2.4 
for an example of the plotted lanes from Deer mice 6’s b-actin densities in 
hepatocyte cultures from both treatments. After plotting the lanes, the program 




Once the cutoff line was drawn, the FIJI wand tool was used to display a 
calculation of the relative area underneath the peaks.  
 
                                              
Figure 2.4: The plotted lanes from DM 6’s b-actin densities in hepatocyte 
culures. The plotted peaks represents the relative density of b-actin’s PCR 
product in the control (top peak) and ZIKV treated (bottom peak) DM6  
hepatocyte culture samples. The number present in each peak indicates the 
percentage of the area under one of the curves compared to the area under the 
other curves. 
 
The final step of the Gel Analyzer program was selecting the label peaks 
option in the analyze pulldown toolbar. The label peaks option displayed a 
percent value of one peak’s area divided by the total area of both peaks.  
The current study utilized the expected PCR product band size for each gene 
with the FIJI program to calculate the percent densities of a control sample’s 




provides a list of all primer sequences and expected product sizes of primer sets 
used in the current project. The peak areas and density comparison percentages 
were compiled into a excel data sheet for statistical analysis in SAS.   
 Immune gene density percentages were all normalized to b-actin in excel 
prior to running an analysis of variance (ANOVA) with SAS. Sources of variation 
in the statistical model included treatment (control vs ZIKV), tissue type, species, 
all possible interactions and residual error. If main effects or interactions were 

























Establishment of Primary Cell Lines 
Establishing liver, kidney, and lung primary cell lines from all three 
selected animal models was attempted in multiple trials using previously 
developed standard operating procedures (SOP). While this was successful for 
lung and kidney primary cell cultures, culturing primary deer mouse and 
Jamaican fruit bat hepatocytes required the development of new SOP during this 
project. Liver, lung, and kidney primary cell cultures, designated as pulmonary 
cell, kidney cell, and hepatocyte cultures were successfully established from 3 
sets of biological replicates in deer mice and Jamaican fruit bats. Primary 
pulmonary cell cultures were the only cell line successfully established in Syrian 
golden hamsters. Hepatocytes were successfully isolated from the hamsters 
using the developed SOP, but cells did not stay viable in culture for long enough 
to be utilized in experimental ZIKV infections. The absence of successfully 
established hepatocytes cultures derived from hamster is attributed to the lack of 
sufficient media type and required growth factors for culturing the cell lines in an 
extended timeline. Between the three established cell lines, the hepatocytes 
were the only cell lines that presented with differing morphologies during culture 
period. Figure 4 shows images of deer mouse hepatocytes from the initial 




between cell morphology of the same cell line between animals. Twenty-one total 
sets of primary cell lines were successfully established from 3 biological 
replicates of each animal model (7 different cell lines) for use in ZIKV 
experimental infection. Table 3.1 shows established primary cell lines for each 
animal. 
 
Table 3.1: A visual representation of established primary cell lines.  
 
Note: Primary cell lines were established from the three selected animal models 
in the current study. An X represents the lack of primary cell cultures derived 
from an animal and/or tissue type. Total n= 21 primary cell cultures. 
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Figure 3.1: Timeline images of primary deer mouse hepatocytes from initial 
isolation to day 12 post inoculation. Images were taken on an inverted light 
microscope at 20x magnification. Notable differences in morphology between 
each timepoint show the progression of the morphology change in the primary 
hepatocytes that has been noted multiple times in previous studies/methods 











Viral Titer of Cell Culture  
Suspension 
 The viral titer of ZIKV treated cell culture suspension from the 72 hour 
timepoint of each established primary cell line was determined using the Reed 
Muench viral titer method. Of the 21 tested samples, only 6 samples showed 
detectable levels of infectious ZIKV. An average tissue culture infectious dose 50 
TCID50 of 1x102.47 infectious virions per ml was calculated between the 6 
samples with detected virus. Infectious virus was detected in all three hamster 
pulmonary cell cultures, and deer mouse 6, Bat 5, and 6 hepatocyte cultures. 
Table 4 includes calculated TCID50s.  
Detection of Viral Ribonucleic Acid 
in 72 Hour Cell Pellet and 
Suspension Sample 
 
 The cell pellet and suspension of ZIKV treated cell cultures were tested for 
the presence of viral RNA through endpoint Polymerase Chain Reaction (PCR) 
with a ZIKV specific primer set designed against a conserved region (within the 
ZIKV Asian lineage) of the E protein sequence. Positive results showed a 362 bp 
PCR product visualized on a 2% agarose gel. 72 hour cell pellet samples from all 
of the established cell lines (n=21) were positive for ZIKV RNA. Two PCR 
reactions (replicates) were run on each cell pellet sample and no differences in 
PCR product bands were present between the replicates. Figure 3.2 displays the 
completed ZIKV RNA PCR products of the 72 hour cell pellet samples visualized 




                     
 
Figure 3.2: Gel image of ZIKV treated cell pellet samples. The PCR products 
ran on the gel with a band at the same size as the +K (PR ZIKV stock virus 
cDNA) are confirmed for the presence of ZIKV RNA in the cell pellet. Every one 
of the 21 collected RNA samples (RT to cDNA) from 72 hour ZIKV treated cell 
pellets were positive for the expected 362 bp product. The unexpected positive 
result of the Bat 1 PMVEC non-infected control sample was resolved after 
resynthesizing the cDNA and re-running the sample with PCR. It was determined 
















PCR analysis of the 72 hour ZIKV treated suspension samples indicated 
that 19 of the 21 samples tested positive for ZIKV RNA in at least one of the 
replicates. Figure 3.3 displays the completed PCR products for all of the 72 hour 
bat primary cell culture suspension samples visualized on a 2% agarose gel. 
Hepatocyte culture suspension derived from bat 7 and kidney cell suspension 
derived from deer mouse 10 did not produce a positive result in either replicates. 
Within the 19 positive suspension samples, only 3 samples tested positive for 
ZIKV RNA in 1 of the 2 replicates. The three samples indicating only 1 positive 
result for ZIKV RNA include pulmonary cell culture suspension derived from deer 
mouse 3 and 4, and hepatocyte culture suspension derived from deer mouse 7. 
Ultimately, 16 samples tested positive twice for ZIKV RNA and 5 of the samples 
had detectable levels of infectious virus in the cell pellet. Interestingly, all of the 
hamster suspension samples and all but one of the bat suspension samples 
tested positive for ZIKV RNA during both trials. Deer mouse primary cell cultures 
were the only samples that did not consistently test positive for ZIKV RNA 
between replicates. Table 3.2 shows detected viral RNA aligned with detected 




       
Figure 3.3: Gel image of ZIKV treated Bat cell suspension samples. The 
PCR products ran on the gel with a band at the same size as the +K (PR ZIKV 
stock virus cDNA) are confirmed for the presence of ZIKV RNA in the cell culture 
suspension. Bat cell culture PCR products displayed on the gel indicate that Bat 
1, 2, and 3 pulmonary cell, Bat 5 and 6 hepatocyte, and Bat 1, 2, and 4 kidney 
cell culture suspensions were positive for ZIKV RNA. As expected, Bat Kidney 
and Bat 5 hepatocyte non-infected control samples did not indicate the presence 
of the expected 362 bp PCR band. Unexpectedly, the hamster 3 pulmonary cell 
culture non-infected control suspension did indicate a positive result. The 
problematic false positive was resolved after resynthesizing the cDNA and re-
running the sample with PCR. It was determined that contamination occurred 













Figure 3.4: Gel image of re-run false positive negative controls. All of the 
false negative results were resolved for the samples except for the non-treated  
(-K) PC cells derived from Bat 1. Interestingly, all of the bat -K samples indicated 
an light band at the expected PCR product size. Potential reasons for the 



















Table 3.2: A comparison of viral RNA and infectious virus detected in 
suspension samples. 
 
Sample ID Viral RNA detected in susp Viral titer 
B1 PC 100 % ND 
B2 PC 100 % ND 
B3 PC 100% ND 
B1 KID 100% ND 
B2 KID 100% ND 
B4 KID 100% ND 
B5 HEP 100% 1x10^2.58 
B6 HEP 100% 1x10^2.58 
B7 HEP 0% ND 
DM 3 PC 50% ND 
DM 4 PC 100% ND 
DM 7 PC 50% ND 
DM 6 KID 100% ND 
DM 7 KID 100% ND 
DM 10 KID 0% ND 
DM 6 HEP 100% 1x10^2.58 
DM 7 HEP 50% ND 
DM 10 HEP 100% ND 
HM 1 PC 100% 1x10^2.26 
HM 2 PC 100% 1x10^2.58 
HM 3 PC 100% 1x10^2.26 
 
Note: The samples listed in the table are ZIKV treated 72 hour cell suspension 
samples tested for viral RNA and infectious virus using endpoint PCR and Reed 
Muench viral titer assay methods. The value listed in the viral RNA column is the 
percentage of  times the sample displayed a band at the expected PCR product 
size (362 bp) over two trials (i.e. 2/2 =100%). The TCID50 value is listed as 






















Examination of Type I Interferon 
 Associated Genes 
  
 Established cell cultures from all three animal models were treated with 
either a control of 2% FBS DMEM or a 1:10 dilution of  ZIKV stock virus and 
incubated for 72 hours prior to sample extraction to compare the effects of ZIKV 
infection on JAK1, STAT1, ISG15, and Oas1b expression levels in parallel with a 
non-infected control. Data collected on the expression levels, of all four genes 
normalized to b-actin are shown in figure 7, 8 and 9. It is important to note, as 
expected, b-actin expression did not show any significant fold changes between 
the different treatments in any of the cell lines.  
 Deer mouse cell cultures displayed the most extensive amount of 
significant gene expression level changes between treatments within the 
selected Type I IFN associated genes. The ZIKV treated samples in all three 
Deer mouse cell culture lines exhibited a highly significant upregulation in JAK1, 
STAT1, ISG15 and Oas1b. ZIKV treatment induced a 3.3 fold increase in JAK1 
(P < 0.0001), 16.6 fold increase in ISG15 (P < 0.0001), and a 5.7 fold increase in 
Oas1b (P=0.0253) steady-state mRNA levels compared to the basal levels in 
control samples. However, no difference was detected in steady-state mRNA 
levels between the ZIKV treatment and control for STAT1 in pulmonary cells 
derived from all three deer mice. ZIKV treatment induced a nearly 5 fold increase 
in STAT1 (P= 0.0027), 2.9 fold increase in ISG15 (P= 0.0035), and a 5.8 fold 
increase in Oas1b (P < 0.0001) steady-state mRNA levels of kidney cells derived 
from all three deer mice compared to the basal levels observed in control 




JAK1 between the ZIKV treatment and control in kidney cells derived from all 
three deer mice. Lastly, ZIKV treatment induced a nearly 3 fold increase in 
STAT1 (P= 0.312), nearly 10 fold increase in ISG15 (P < 0.0001), and a 16.2 fold 
increase in Oas1b (P= 0.0002) steady-state mRNA levels in hepatocytes derived 
from all three deer mice compared to the basal levels observed in control 
samples. No difference was detected in JAK1 steady-state mRNA levels of  
hepatocytes derived from all three deer mice. Figure 3.5 visualizes the 
differences in steady-state mRNA levels of JAK1, STAT1, Oas1b, and ISG15 for 
















Figure 3.5a: Expression levels of JAK1, STAT1 for Deer mouse samples. 
Graphs display effects of ZIKV treatment on expression of the selected Type I 
IFN associated gene, JAK1, in established primary cell cultures derived from 
deer mice. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell 
culture media (cell line dependent) and control (-K) samples were treated with 
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample normalized PCR product 
density values are represented as blue bars (n= 3 per graph) and control sample 
values are represented by the orange bars (n= 3 per graph). Control and ZIKV 
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and 
sets with three asterisks indicate a highly significant p value (< 0.01) in steady-
state mRNA levels between treatments. The value in the white box to the right of 
each set of sample bar graphs indicates the fold change in steady-state mRNA 






Figure 3.5b: Expression levels of STAT1 for Deer mouse samples. Graphs 
display effects of ZIKV treatment on expression of the selected Type I IFN 
associated gene, STAT1, in established primary cell cultures derived from deer 
mice.  ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell 
culture media (cell line dependent) and control (-K) samples were treated with 
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour  timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample normalized PCR product 
density values are represented as blue bars (n= 3 per graph) and control sample 
values are represented by the orange bars (n= 3 per graph). Control and ZIKV 
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and 
sets with three asterisks indicate a highly significant p value (< 0.01) in steady-
state mRNA levels between treatments. The value in the white box to the right of 
each set of sample bar graphs indicates the fold change in steady-state mRNA 






Figure 3.5c: Expression levels of ISG15 for Deer mouse samples. Graphs 
display effects of ZIKV treatment on expression of the selected Type I IFN 
associated gene, ISG15, in established primary cell cultures derived from deer 
mice.  ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell 
culture media (cell line dependent) and control (-K) samples were treated with 
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour  timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample normalized PCR product 
density values are represented as blue bars (n= 3 per graph) and control sample 
values are represented by the orange bars (n= 3 per graph). Control and ZIKV 
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and 
sets with three asterisks indicate a highly significant p value (< 0.01) in steady-
state mRNA levels between treatments. The value in the white box to the right of 
each set of sample bar graphs indicates the fold change in steady-state mRNA 






Figure 3.5d: Expression levels of Oas1b for Deer mouse samples. Graphs 
display effects of ZIKV treatment on expression of the selected Type I IFN 
associated gene, Oas1b, in established primary cell cultures derived from deer 
mice. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell 
culture media (cell line dependent) and control (-K) samples were treated with 
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour  timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample normalized PCR product 
density values are represented as blue bars (n= 3 per graph) and control sample 
values are represented by the orange bars (n= 3 per graph). Control and ZIKV 
treated sets with a single asterisk (*) indicate a significant p value (0.5 to 0.1) and 
sets with three asterisks indicate a highly significant p value (< 0.01) in steady-
state mRNA levels between treatments. The value in the white box to the right of 
each set of sample bar graphs indicates the fold change in steady-state mRNA 
















In contrast to deer mouse cultures, Jamaican fruit bat cultures had the 
lowest amount of significant expression changes in steady-state mRNA levels of 
the selected Type I IFN associated genes between the three animal models. The 
ZIKV treatment in all three Jamaican fruit bat cell culture lines did not induce any 
significant increases in JAK1, STAT1, ISG15 and Oas1b steady-state mRNA 
levels. The largest fold change observed in the bat samples was a nearly 2 fold 
increase of STAT1 steady-state mRNA levels in hepatocytes derived from all 
three bats. However, t-test statistical analysis of the hepatocyte STAT1 fold 
change between the ZIKV treatment and control yielded a non-significant P value 
(P= 0.0793). Figure 3.6 visualizes the differences in steady-state mRNA levels of 













Figure 3.6a: Expression levels of JAK1 for Jamaican fruit bat samples. 
Graphs display effects of ZIKV treatment on expression of the selected Type I 
IFN associated gene, JAK1, in established primary cell cultures derived from 
bats. ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell culture 
media (cell line dependent) and control (-K) samples were treated with cell 
culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample PCR product density 
values (normalized to b-actin) are represented as blue bars (n= 3 per graph) and 
control sample values are represented by the orange bars (n= 3 per graph). 
Control and ZIKV treated sets with a single asterisk (*) indicate a significant p 
value (0.5 to 0.1) and sets with three asterisks indicate a highly significant p 
value (< 0.01) in the difference of steady-state mRNA levels between treatments. 
The value in the white box to the right of each set of sample bar graphs indicates 
the fold change in steady-state mRNA levels between the control and ZIKV 




































Figure 3.6b: Expression levels of STAT1 for Jamaican fruit bat samples. 
Graphs display effects of ZIKV treatment on expression of the selected Type I 
IFN associated gene, STAT1, in established primary cell cultures derived from 
bats.  ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell 
culture media (cell line dependent) and control (-K) samples were treated with 
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample PCR product density 
values (normalized to b-actin) are represented as blue bars (n= 3 per graph) and 
control sample values are represented by the orange bars (n= 3 per graph). 
Control and ZIKV treated sets with a single asterisk (*) indicate a significant p 
value (0.5 to 0.1) and sets with three asterisks indicate a highly significant p 
value (< 0.01) in the difference of steady-state mRNA levels between treatments.  
The value in the white box to the right of each set of sample bar graphs indicates 
the fold change in steady-state mRNA levels between the control and ZIKV 






































Figure 3.6c: Expression levels of ISG15 for Jamaican fruit bat samples. 
Graphs display effects of ZIKV treatment on expression of the selected Type I 
IFN associated gene, ISG15, in established primary cell cultures derived from 
bats.  ZIKV samples were treated with a 1:10 PR ZIKV stock dilution in cell 
culture media (cell line dependent) and control (-K) samples were treated with 
cell culture media only. Synthesized cDNA from total cell RNA samples at the 72 
hour timepoint for the control and ZIKV treated samples were ran in semi-
quantitative PCR for each gene. ZIKV treated sample PCR product density 
values (normalized to b-actin) are represented as blue bars (n= 3 per graph) and 
control sample values are represented by the orange bars (n= 3 per graph). 
Control and ZIKV treated sets with a single asterisk (*) indicate a significant p 
value (0.5 to 0.1) and sets with three asterisks indicate a highly significant p 
value (< 0.01) in the difference of steady-state mRNA levels between treatments. 
The value in the white box to the right of each set of sample bar graphs indicates 
the fold change in steady-state mRNA levels between the control and ZIKV 
treated sample.  
 
 
  Similar to the deer mice, hamster samples displayed a highly significant 
difference in the expression of two out of the three examined Type I IFN 
associated genes. ZIKV treatment induced a nearly 5 fold increase in JAK1 (P < 
0.0095) and a 3.3 fold increase in Oas1b (P < 0.00052) steady-state mRNA 



































levels observed in control samples. However, no difference was detected in 
STAT1’s steady-state mRNA levels between the ZIKV treatment and control for 
pulmonary cells derived from all three hamsters. Figure 3.7 visualizes the 
differences in steady-state mRNA levels of JAK1, STAT1 and Oas1b for the 























Figure 3.7: Expression levels of JAK1, STAT1, and Oas1b for Syrian golden 
hamster samples. Graphs display effects of ZIKV treatment on expression of 
the selected Type I IFN associated genes in primary pulmonary cell cultures 
derived from hamsters.  ZIKV samples were treated with a 1:10 PR ZIKV stock 
dilution in cell culture media(cell line dependent) and control (-K) samples were 
treated with cell culture media only. Synthesized cDNA from total cell RNA 
samples at the 72 hour timepoint for the control and ZIKV treated samples were 
ran in semi-quantitative PCR for each gene. ZIKV treated samples PCR product 
density values (normalized to b-actin) are represented as blue bars (n=3 per 
graph) and control sample values are represented by the orange bars (n=3 per 
graph). Control and ZIKV treated sets with a single asterisk (*) indicate a 
significant p value (0.5 to 0.1) and sets with three asterisks indicate a highly 
significant p value (< 0.01) in steady-state mRNA expression levels between 
treatments. The value in the white box to the right of each set of sample bar 
graphs indicates the fold change in steady-state mRNA levels between the 
















CHAPTER IV  
DISCUSSION & CONCLUSION 
Discussion 
The Type I Interferon (IFN) response’s potent restriction on flaviviral 
invasion and replication has been characterized in multiple previous studies 
involving multiple host species [20, 133, 134]. In order to combat the restrictive 
effects of the suppressive effects of the Type I IFN response, Flaviviruses have 
evolved a relatively extensive number of species specific mechanisms using a 
combination of the sfRNA and NS proteins to subvert the deleterious effects of 
the host’s innate immune system response [2, 15, 30, 78, 135]. Zika virus (ZIKV), 
a newly emerging member of the flavivirus family, has also demonstrated the 
capacity to effectively repress the Type I IFN response in human and non-human 
primates [3, 30, 93]. ZIKV has been shown to utilize the NS1, NS2B-3 complex, 
NS4B, and NS5 proteins in combination with the sfRNA to mediate its subversion 
of the host cell response. In consideration of the employed ZIKV non-structural 
proteins, NS5’s influence on the expression of Type I IFN associated interferon 
stimulated genes (ISG) has been the most clearly elucidated in previous ZIKV 
research [2, 80, 93]. The reasoning behind the extensive amount of research into 
ZIKV’s NS5 activity is founded by the necessity of the NS5 protein’s effective 
antagonism on the phosphorylation of the host cell’s STAT2 to generate a 




in the Type I IFN pathway that promotes the induction of hundreds of ISGs [81]. 
In humans, the STAT2 protein is effectively antagonized by proteosomal 
degradation mediated through the interaction of the ZIKV NS5. In contrast, the 
mouse STAT2 protein structure differs enough from the human counterpart to 
resist degradation by the ZIKV NS5 protein [93]. The resistance of the mouse 
STAT2 protein to NS5 antagonism allows for the induction of a robust type I IFN 
response in host cells generating a highly protective immune response that 
significantly limits ZIKV replication [3]. Therefore, current research studies 
involving ZIKV have predominantly used the widely accepted Type I IFN 
immunodeficient mouse model to study viral pathogenicity and test vaccine 
candidates [27, 41, 95]. However, the use of an animal model without a complete 
IFN response creates a number of concerns regarding the findings of the studies 
in their application to animals with intact immune responses, such as humans. As 
well, previous research has elucidated the relationship between ZIKV’s capacity 
to suppress the host cell immune response in humans, non-human primates, and 
mice, but a significant lack of insight into the antagonistic effects of ZIKV on the 
host cell response in a diversity of mammalian species currently exists. In the 
current study, we supplement the lack of data regarding the susceptibility and 
host cell immune response of primary cell lines derived from three 
immunocompetent animal models to ZIKV infection. We also provide the pilot 
data to warrant further research into the development of two novel 




During the current study, 7 different primary cell lines were derived from 
Syrian golden hamsters, Jamaican fruit bats, and deer mice. Of the established 
cell lines, research conducted with primary hepatocyte cell cultures from deer 
mice and Jamaican fruit bats has not been published in any research papers to 
date. In order to establish the primary hepatocyte cell lines, a protocol was 
designed and optimized for isolating and culturing the selected cell type using the 
widely accepted two-step liver perfusion method developed for rat hepatocyte 
isolation as a foundation [130]. The developed protocol has shown consistency in 
yielding high concentrations of viable hepatocytes from all three animal models. 
However, further research into the optimal media type for hamsters is required to 
culture hamster hepatocytes for longer than a week. Notable differences in 
hepatocyte morphology in both deer mouse and Jamaican fruit bat cell lines in 
prolonged cultures indicate the potential loss of hepatic phenotype functions such 
as production of metabolizing enzymes and transport systems mentioned in 
previous studies involving rat and mouse hepatocytes [122, 128]. It would be 
beneficial for future studies to investigate which hepatocyte functions are lost in 
cell culture. However, even with the potential loss of certain functions, the deer 
mouse and bat hepatocytes established in this study still provided a sufficient 
model for investigating the aims of the current study.  
The investigation of susceptibility, and permissiveness to replication of 
ZIKV in primary cell cultures from the selected animal models yielded surprising 
results in consideration of previous research. We show that all 21 of the 




presence of viral RNA in ZIKV treated cell pellet samples. Viral RNA was also 
present in the suspension of 8 out of 9 bat cell cultures, 8 out of 9 deer mouse 
cell cultures, and 3 out of 3 hamster cell cultures. Within the deer mouse 
cultures, 3 out of the 8 infected cell culture suspensions only tested positive for 
viral RNA in 50% of the conducted Polymerase Chain Reaction (PCR) assays (2 
replicates). The ZIKV primer set employed for viral Ribonucleic Acid (RNA)  
detection was has exhibited the capacity to detect viral RNA at a 1x106 dilution of 
stock virus, indicating a relatively high sensitivity for the viral RNA. Therefore, we 
conclude that the inconsistent results were most likely due to extremely low 
concentrations of viral RNA possibly due to a restriction in the shedding of ZIKV 
from host cells in the tested samples. The results of the cell culture suspension 
and cell pellet testing for ZIKV RNA indicate that at least 16 of the 19 primary cell 
cultures are susceptible to viral infection, permissive to ZIKV replication and 
shedding of virions in suspension. It is also important to note that Jamaican fruit 
bat non-treated suspension samples indicated very light bands at the expected 
ZIKV PCR product size throughout ZIKV RNA testing. We believe the consistent 
detection of false positives in bat samples may be caused by unexpected 
annealing on bat cell mRNAs. A NCBI blast of the ZIKV PCR primer against the 
recently sequenced Artibeus jamaicensis genome resulted in multiple sequence 
alignments with 98% homology or higher. Therefore, the unexpected false 
positives may be a result of unexpected mispriming on bat mRNA resulting in a 




detection of ZIKV RNA in bat samples would either need to be optimized from the 
current set or redesigned to alleviate the false positive issues.  
The current study also supplemented the results of detected viral RNA in 
suspension by testing ZIKV treated cell suspensions for levels of infectious virus 
to determine the permissiveness of host cells for shedding infectious virus. We 
show that 6 primary cell culture samples have detectable levels infectious virus in 
their suspension. The most surprising result within these findings was the 
detected of infectious virus deer mouse 6’s hepatocyte culture. Infectious virus 
was also detected in two bat cell lines, bat 5 and 6 hepatocytes, and all three of 
the Syrian golden hamster cultures. Considering the detectable levels of viral 
RNA and infectious virus in suspension, the lack of consistent detection of viral 
RNA and not detecting infectious virus in deer mouse pulmonary and kidney cells 
may indicate insight into the tissue tropism of ZIKV in deer mice. ZIKV was able 
to efficiently replicate and be shed into the suspension of the hepatocyte cells 
derived from deer mouse 6 in high enough titers to be detected in the viral titer 
assays. These results may indicate ZIKV’s tropism for hepatocytes in deer mice. 
Similar to the deer mouse samples, infectious virus was only isolated in bat 
hepatocyte culture, which may indicate a tropism for hepatocytes in bat as well. 
However, further research involving in vivo work with deer mice and bats would 
be required to confirm these proposed notions derived from these findings. Aside 
from the consideration of tissue tropism, these results may provide an interesting 
insight into the differences between animals of the same species in their 




detection of infectious virus was varied between biological replicates in the same 
cell culture tissue type. The differences between biological replicates could be 
caused different alleles expressed in important ZIKV restrictive immune genes 
between individuals in the same species. However, as with the tissue tropism 
hypothesis, future research would need to investigate the effects of allelic 
differences within a population of the samples species on flaviviral replication to 
provide support for the proposed notion.  
Our findings on the primary cell culture are consistent with previous in vivo 
ZIKV research demonstrating the susceptibility and seroconversion of Jamaican 
fruit bat and Syrian golden hamsters [96, 117]. However, we were surprised to 
find that deer mouse derived primary cell lines were positive for ZIKV RNA in a 
majority of the suspensions samples as well as testing positive in all of the cell 
pellet samples. These results seemingly contradict the findings of Regina et al.’s 
work with ZIKV and deer mice. The previous research study inoculated a 
diversity of species with two ZIKV isolates and found that virus was not 
detectable in sera and detectable levels of neutralizing antibodies were absent 
[108]. The differences in Regina et al.’s results and the current study’s findings 
may be attributed to the animal level (in vitro versus in vivo) that the studies were 
conducted at. A considerable drawback of conducting virus research in vitro is 
the lack of immune cells and the humoral branch of the immune response. 
Therefore, it is possible that deer mouse primary cell cultures may be susceptible 
to ZIKV infection in vitro, but a whole animal model is able to generate a 




studies was the source of the deer mice employed in each study. Regina et al.’s 
work involved wild caught deer mice whereas the current study utilized deer mice 
from UNCO’s colony housed in HEPA-filtered cages. Multiple recent research 
studies evaluating the immune response of multiple species of wild caught rodent 
species (mainly rats and mice) compared to their laboratory raised “clean room” 
counter parts yielded data supporting the presence of significant differences 
between the wild caught rodents ability to mediate and clear pathogens 
compared to the “clean room” rodents [136]. The noted differences in immune 
responses between wild caught rodents and lab rodents may provide an answer 
to the differences in susceptibility and permissiveness to replication observed 
between our results and Regina et al.’s findings, but further research would be 
required to provide evidence for the proposed notion. 
The data yielded from the semi-quantitative PCR analysis of Type I IFN 
associated immune expression provides noteworthy insights into the immune 
response of all three animal models. Deer mouse samples displayed the greatest 
number of significant fold changes across all tissue types in all of the examined 
genes between treatments, aside from JAK1. These findings support the results 
indicating that deer mouse primary cell lines were susceptible to ZIKV infection. 
The robust induction of STAT1, ISG15 and Oas1b indicated by the large fold 
changes of expression (3, 10, and 9 respectively) between treatments in all three 
tissue types shows that the Type I IFN response is being triggered by an RLR, 
most likely RIG-I, and the pathway is activated to the level of ISG expression. 




research for their potent anti-flaviviral effects, provides evidence that the deer 
mouse STAT2 is not being effectively antagonized by the ZIKV NS5 protein and 
can therefore complete the downstream activation of ISGs. These findings 
denote a unique outcome of ZIKV infections in deer mice that has not been 
characterized in any animal model to date. It is possible considering the outcome 
of the experimental infections, that deer mice could act as a reservoir model for 
ZIKV future research.  
The gene expression results of the Jamaican fruit bat primary cell cultures 
show a stark contrast in fold change induction relative to the deer mouse 
samples. Only one observed fold increase in gene expression occurred in all of 
the tested bat samples. Bat hepatocytes indicated a 2-fold increase in STAT1 
expression, but the change was determined insignificant after the conducting 
statistical analysis. The lack of a observed fold changes in the bat Type I IFN 
response associated genes in combination with the detection of ZIKV RNA in all 
but one bat primary cell culture (B7 hepatocyte), suggests that Jamaican fruit 
bats are susceptible to ZIKV infection and are not significantly upregulating the 
expression of JAK1, STAT1, or ISG15 in response to viral infection. There are 
three possible causes for the lack of increased ISG expression in the bat 
samples. Considering the well-established insights into flaviviral Type I IFN 
immune suppression bat cell, RLRs may be detecting viral epitopes and 
activating the signaling pathway, but ZIKV is able to effectively antagonize a vital 
signaling protein to suppress upregulation of ISGs. The effective antagonism of 




the ZIKV NS5 protein or at another step in the pathway that is unique to 
Jamaican fruit bats. It is also possible that the lack of an observable fold change 
in ISG15 may be due to bat cells constitutively expressing relatively high levels of 
IFN-a and a subset of ISGs. A recent study by Zhou et al. indicates that 
Australian black flying fox kidney cell lines (Pteropus alecto) constitutively 
express high levels of IFN-a sequences in comparison to human HEK293T cells 
and the expression levels of the IFN-a gene is not significantly upregulated in 
response to viral infection by Hendra virus, Pulau virus (PulV), and Sendai virus. 
Along with IFN-a, levels of Type I IFN genes including Oas1, MX1 and ISG15 
were shown to have high constitutive expression in normal bat cells [137]. These 
findings suggest that bats may be constitutively expressing high levels of potent 
antiviral ISGs that are able to restrict high levels of viral replication while also 
eliminating the need for a robust Type I IFN response in order to clear a viral 
infection. Lastly, bat cell lines may be activing the Type III IFN pathway in 
response to ZIKV infection, instead of the expected Type I IFN response. Unlike 
human and mouse cells, black flying fox cells have been shown express Type III 
IFN receptors on a wide variety of tissue types. The Type III IFN response was 
also shown to be preferentially activated following experimental infection with 
Tioman virus (Paramyxovirus) in black flying fox splenocytes. In contrast, the 
Type I IFN response was shown to be downregulated during the experimental 
infection in the splenocytes [138]. Within the same study, Zhou et al. 
demonstrated that induction of the Type III IFN response, specifically PaFeTO5 




growth and pathology. The authors utilized PulV instead of Tioman virus to 
demonstrate the antiviral qualities of the Type III IFN response, because PulV 
displays observable CPE in PaFeTO5 cells [139]. However, these unique 
characteristics of black flying fox cells have not yet been demonstrated across 
multiple bat species. Although the discussed explanations for the lack of a strong 
ISG induction in the Jamaican fruit bat cells are drawn from previous research in 
bat cells, an extensive amount of research into elucidating the Type I and Type III 
IFN response in Jamaican fruit bats is necessary before generating any traction 
for the proposed reasoning.  
Due to the lack of kidney cell and hepatocyte cell lines, the gene 
expression results for the Syrian golden hamster is considerably limited in its 
findings compared to the deer mice and Jamaican fruit bats. Despite the 
limitations of only examining one cell culture type, the data yielded from the 
hamster primary pulmonary cell lines indicates that JAK1 had a significantly 
higher up-regulation in hamster pulmonary cell lines compared to the deer mouse 
cell lines (5 fold and 3.3 fold, respectively). Interestingly, Oas1b only had a 
moderate upregulation compared to the deer mice pulmonary cell lines (3.3 and 
5.7, respectively). These findings taken with the results of the ZIKV RNA and 
viral titer detection assays indicate that Syrian golden hamsters are susceptible 
to ZIKV infection and it is postulated that the Type I IFN response is suppressed 
by ZIKV at some point between JAK1 and the induction of ISGs effectively 






This pilot study has provided data to support further research into all three 
animal models for ZIKV research. Each animal model displayed a unique 
outcome in response to ZIKV infection compared not only the other animals in 
the study, but also to humans and immunocompetent lab mice. As discussed in 
the introduction, a robust induction of ISGs is inhibited by ZIKV NS5 in humans. 
The inhibition of ISG production in humans allows for ZIKV to efficiently replicate 
and generate a productive infection in human cells. However, immunocompetent 
lab mice’s ISG induction is not effectively suppressed by ZIKV, and therefore is 
able to generate a protective ISG mediated response [3, 83, 93]. Data from the 
deer mouse primary cell cultures indicate the potential for development as a 
novel non-pathogenic model for ZIKV and Syrian golden hamsters as disease 
models. Interestingly, the data yielded  from the Jamaican fruit bat primary cell 
cultures does not clearly indicate the category of ZIKV animal model that the bats 
would fall in. Future research further investigating the expression levels of 
different transduction protein genes along the signaling pathway and other ISGs 
of the Type I IFN response during ZIKV infection with qPCR and deep seq RNA 
analysis would be beneficial to confirm these findings and provide more insight 
into the immune response pathway for all three animals. As well, examining the 
phosphorylation levels of STAT1 and STAT2 with Western Blot assays in ZIKV 
treated primary cell lines from Syrian golden hamsters and Jamaican fruit bats 
would provide the necessary insight to determine if either of the species STAT 




alignment with the long term goals of this pilot study, results indicate that the 
three compared species could be used for future development of effective 
















































1. Moureau, G., et al., New Insights into Flavivirus Evolution, Taxonomy and 
Biogeographic History, Extended by Analysis of Canonical and Alternative 
Coding Sequences. PLoS One, 2015. 10(2). 
2. Best, S.M., The Many Faces of the Flavivirus NS5 Protein in Antagonism 
of Type I Interferon Signaling. Journal of Virology, 2017. 91(3): p. e01970-
16. 
3. Cumberworth, S.L., et al., Inhibition of type I interferon induction and 
signalling by mosquito-borne flaviviruses. Cellular Microbiology, 2017. 
19(5): p. e12737-n/a. 
4. Heinz, F.X. and K. Stiasny, Flaviviruses and flavivirus vaccines. Vaccine, 
2012. 30(29): p. 4301-4306. 
5. Daep, C.A., J.L. Muñoz-Jordán, and E.A.J.J.o.N. Eugenin, Flaviviruses, an 
expanding threat in public health: focus on dengue, West Nile, and 
Japanese encephalitis virus. 2014. 20(6): p. 539-560. 
6. Hertzog, J., et al., Infection with a Brazilian isolate of Zika virus generates 
RIG-I stimulatory RNA and the viral NS5 protein blocks type I IFN 





7. Brady, O.J., et al., Refining the global spatial limits of dengue virus 
transmission by evidence-based consensus. PLoS Negl Trop Dis, 2012. 
6(8): p. e1760. 
8. Bhatt, S., et al., The global distribution and burden of dengue. Nature, 
2013. 496(7446): p. 504-7. 
9. Centers for Disease Control and Prevention, N.C.f.E.a.Z.I.D., WNV: Final 
Cumulative Maps & Data for 1999-2018. 2019, Centers for Disease 
Control and Prevention: CDC West Nile Virus Homepage. 
10. W.H.O., A Global Strategy to Eliminate Yellow Fever Epidemics 2017-
2026. World Health Organization: WHO Emergencies Preparedness: YFV. 
11. Agrelli, A., et al., ZIKA virus entry mechanisms in human cells. Infection, 
Genetics and Evolution, 2019. 69: p. 22-29. 
12. Smit, J.M., et al., Flavivirus Cell Entry and Membrane Fusion. Viruses, 
2011. 3(2): p. 160-171. 
13. Gould, E.A. and T. Solomon, Pathogenic flaviviruses. Lancet, 2008. 
371(9611): p. 500-9. 
14. Apte-Sengupta, S., D. Sirohi, and R.J. Kuhn, Coupling of replication and 
assembly in flaviviruses. Current Opinion in Virology, 2014. 9: p. 134-142. 
15. Fernandez-Garcia, M.-D., et al., Pathogenesis of Flavivirus Infections: 
Using and Abusing the Host Cell. Cell Host & Microbe, 2009. 5(4): p. 318-
328. 
16. Rossignol, E.D., et al., Zika virus induced cellular remodelling. Cell 




17. Lindenbach, B., H.J. Thiel, and C.M. Rice, Flaviviridae: The viruses and 
their replication. 2007. 1101-1151. 
18. Zhang, Y., et al., Conformational Changes of the Flavivirus E 
Glycoprotein. Structure (London, England : 1993), 2004. 12(9): p. 1607-
1618. 
19. Collins, M.H. and S.W. Metz, Progress and Works in Progress: Update on 
Flavivirus Vaccine Development. Clinical Therapeutics, 2017. 39(8): p. 
1519-1536. 
20. Wu, Y., et al., Zika virus evades interferon-mediated antiviral response 
through the co-operation of multiple nonstructural proteins in vitro. Cell 
Discovery, 2017. 3: p. 17014. 
21. Tripathi, S., et al., A novel Zika virus mouse model reveals strain specific 
differences in virus pathogenesis and host inflammatory immune 
responses. PLOS Pathogens, 2017. 13(3): p. e1006258. 
22. Lin, H.-H., et al., Zika virus structural biology and progress in vaccine 
development. Biotechnology Advances, 2018. 36(1): p. 47-53. 
23. W.H.O., WHO ZIKV Vaccine Pipeline Tracker. 2019, World Health 
Organization: WHO Immunizations, Vaccines, and Biologicals. 
24. Wikan, N. and D.R. Smith, Zika virus: history of a newly emerging 
arbovirus. The Lancet Infectious Diseases, 2016. 16(7): p. e119-e126. 
25. Hamel, R., et al., Biology of Zika Virus Infection in Human Skin Cells. 




26. Simpson, D.I.H., Zika virus infection in man. Transactions of the Royal 
Society of Tropical Medicine and Hygiene, 1964. 58(4): p. 335-338. 
27. Lazear, Helen M., et al., A Mouse Model of Zika Virus Pathogenesis. Cell 
Host & Microbe, 2016. 19(5): p. 720-730. 
28. Song, B.-H., et al., Zika virus: History, epidemiology, transmission, and 
clinical presentation. Journal of Neuroimmunology, 2017. 308: p. 50-64. 
29. Beaver, J.T., et al., Evolution of Two Major Zika Virus Lineages: 
Implications for Pathology, Immune Response, and Vaccine Development. 
Frontiers in immunology, 2018. 9: p. 1640-1640. 
30. Bowen, J.R., et al., Zika Virus Antagonizes Type I Interferon Responses 
during Infection of Human Dendritic Cells. PLoS Pathogens, 2017. 13(2). 
31. W.H.O., ZIKV Epidemiology Report for July 2019. 2019, World Health 
Organization: WHO ZIKV Epidemology. p. 1-14. 
32. Centers for Disease Control and Prevention, N.C.f.E.a.Z.I.D., Zika Virus 
Statistics and Maps. 2019, Centers for Disease Control and Prevention 
CDC ZIKV Homepage. 
33. Centers for Disease Control and Prevention, N.C.f.E.a.Z.I.D., Zika Travel 
Information. 2019, Centers for Disease Control and Prevention: CDC 
Traveler’s Health. 
34. Gong, Z., Y. Gao, and G.-Z. Han, Zika Virus: Two or Three Lineages? 




35. Shen, S., et al., Phylogenetic analysis revealed the central roles of two 
African countries in the evolution and worldwide spread of Zika virus. Virol 
Sin, 2016. 31(2): p. 118-30. 
36. Smith, D.R., et al., African and Asian Zika Virus Isolates Display 
Phenotypic Differences Both In Vitro and In Vivo. 2018. 98(2): p. 432-444. 
37. Bowen, J.R., et al., Zika Virus Antagonizes Type I Interferon Responses 
during Infection of Human Dendritic Cells. PLOS Pathogens, 2017. 13(2): 
p. e1006164. 
38. Smith, D.R., et al., African and Asian Zika Virus Isolates Display 
Phenotypic Differences Both In Vitro and In Vivo. The American Journal of 
Tropical Medicine and Hygiene, 2018. 98(2): p. 432-444. 
39. Kumar, A., et al., Human Sertoli cells support high levels of Zika virus 
replication and persistence. Scientific Reports (Nature Publisher Group), 
2018. 8: p. 1-11. 
40. Chan, J.F.-W., et al., Differential cell line susceptibility to the emerging 
Zika virus: implications for disease pathogenesis, non-vector-borne human 
transmission and animal reservoirs. Emerging Microbes &Amp; Infections, 
2016. 5: p. e93. 
41. Dowall, S.D., et al., A Susceptible Mouse Model for Zika Virus Infection. 
PLOS Neglected Tropical Diseases, 2016. 10(5): p. e0004658. 
42. Guedes, D.R.D., et al., Zika virus replication in the mosquito Culex 





43. Diallo, D., et al., Zika Virus Emergence in Mosquitoes in Southeastern 
Senegal, 2011. PLOS ONE, 2014. 9(10): p. e109442. 
44. Gubler, D.J., The Global Emergence/Resurgence of Arboviral Diseases 
As Public Health Problems. Archives of Medical Research, 2002. 33(4): p. 
330-342. 
45. Asad, H. and D.O. Carpenter, Effects of climate change on the spread of 
zika virus: a public health threat. Rev Environ Health, 2018. 33(1): p. 31-
42. 
46. Paz, S. and J.C. Semenza, El Nino and climate change--contributing 
factors in the dispersal of Zika virus in the Americas? Lancet, 2016. 
387(10020): p. 745. 
47. Counotte, M.J., et al., Sexual transmission of Zika virus and other 
flaviviruses: A living systematic review. PLoS Med, 2018. 15(7): p. 
e1002611. 
48. Mead, P.S., et al., Zika Virus Shedding in Semen of Symptomatic Infected 
Men. New England Journal of Medicine, 2018. 378(15): p. 1377-1385. 
49. El Costa, H., et al., ZIKA virus reveals broad tissue and cell tropism during 
the first trimester of pregnancy. Scientific Reports, 2016. 6: p. 35296. 
50. Ribeiro, M.R., et al., Zika-virus-infected human full-term placental explants 
display pro-inflammatory responses and undergo apoptosis. Arch Virol, 
2018. 163(10): p. 2687-2699. 
51. Yuan, S., et al., Commentary: Teratogenic effects of the Zika virus and the 




52. Bayer, A., et al., Type III Interferons Produced by Human Placental 
Trophoblasts Confer Protection against Zika Virus Infection. Cell Host 
Microbe, 2016. 19(5): p. 705-12. 
53. Quicke, Kendra M., et al., Zika Virus Infects Human Placental 
Macrophages. Cell Host & Microbe, 2016. 20(1): p. 83-90. 
54. Kumar, M., et al., A guinea pig model of Zika virus infection. 2017. 14(1): 
p. 75. 
55. Krow-Lucal, E.R., B.J. Biggerstaff, and J.E. Staples, Estimated Incubation 
Period for Zika Virus Disease. Emerging Infectious Diseases, 2017. 23(5): 
p. 841-844. 
56. Hasan, S.S., et al., A human antibody against Zika virus crosslinks the E 
protein to prevent infection. Nature Communications, 2017. 8(1): p. 14722. 
57. Heinz, F.X. and K. Stiasny, The Antigenic Structure of Zika Virus and Its 
Relation to Other Flaviviruses: Implications for Infection and 
Immunoprophylaxis. Microbiology and Molecular Biology Reviews, 2017. 
81(1): p. e00055-16. 
58. Miner, J.J. and M.S. Diamond, Zika Virus Pathogenesis and Tissue 
Tropism. Cell Host & Microbe, 2017. 21(2): p. 134-142. 
59. Alcendor, D.J., Zika Virus Infection of the Human Glomerular Cells: 
Implications for Viral Reservoirs and Renal Pathogenesis. The Journal of 
Infectious Diseases, 2017. 216(2): p. 162-171. 
60. Ann-Claire, G., et al., Detection of Zika Virus in Urine. Emerging Infectious 




61. Hattori, S., et al., Relationship Between Increased Expression of the 
Axl/Gas6 Signal Cascade and Prognosis of Patients with Upper Tract 
Urothelial Carcinoma. 2016. 23(2): p. 663-670. 
62. Nowakowski, T.J., et al., Expression Analysis Highlights AXL as a 
Candidate Zika Virus Entry Receptor in Neural Stem Cells. Cell Stem Cell, 
2016. 18(5): p. 591-6. 
63. Meertens, L., et al., Axl Mediates ZIKA Virus Entry in Human Glial Cells 
and Modulates Innate Immune Responses. Cell Reports, 2017. 18(2): p. 
324-333. 
64. Ma, W., et al., Zika Virus Causes Testis Damage and Leads to Male 
Infertility in Mice. Cell, 2016. 167(6): p. 1511-1524.e10. 
65. Liu, S.F., et al., AXL-Mediated Productive Infection of Human Endothelial 
Cells by Zika Virus. Circulation Research, 2016. 119(11): p. 1183-1183. 
66. Persaud, M., et al., Infection by Zika viruses requires the transmembrane 
protein AXL, endocytosis and low pH. Virology, 2018. 518: p. 301-312. 
67. Coelho, S.V.A., et al., Development of standard methods for Zika virus 
propagation, titration, and purification. Journal of Virological Methods, 
2017. 246: p. 65-74. 
68. Hastings, A.K., et al., TAM Receptors Are Not Required for Zika Virus 
Infection in Mice. Cell Reports, 2017. 19(3): p. 558-568. 
69. Vicenti, I., et al., Comparative analysis of different cell systems for Zika 
virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro. 




70. Strange, D.P., et al., Axl Promotes Zika Virus Entry and Modulates the 
Antiviral State of Human Sertoli Cells. mBio, 2019. 10(4): p. e01372-19. 
71. Chen, J., et al., AXL promotes Zika virus infection in astrocytes by 
antagonizing type I interferon signalling. Nature Microbiology, 2018. 3(3): 
p. 302-309. 
72. Wang, Z.Y., et al., Axl is not an indispensable factor for Zika virus infection 
in mice. JOURNAL OF GENERAL VIROLOGY, 2017. 98(8): p. 2061-
2068. 
73. Hamel, R., et al., Biology of Zika Virus Infection in Human Skin Cells. 
Journal of Virology, 2015. 89(17): p. 8880-8896. 
74. Briant, L., et al., Role of skin immune cells on the host susceptibility to 
mosquito-borne viruses. Virology, 2014. 464-465: p. 26-32. 
75. Tabata, T., et al., Zika Virus Targets Different Primary Human Placental 
Cells, Suggesting Two Routes for Vertical Transmission. Cell Host & 
Microbe, 2016. 20(2): p. 155-166. 
76. Sompayrac, L., How the Immune System Works Vol. 5th edition 2016: 
Wiley Blackwell 151. 
77. Loo, Y.-M., et al., Distinct RIG-I and MDA5 signaling by RNA viruses in 
innate immunity. Journal of virology, 2008. 82(1): p. 335-345. 
78. Muñoz-Jordan, J.L. and B.L. Fredericksen, How Flaviviruses Activate and 




79. Fredericksen, B.L., et al., Establishment and maintenance of the innate 
antiviral response to West Nile Virus involves both RIG-I and MDA5 
signaling through IPS-1. Journal of virology, 2008. 82(2): p. 609-616. 
80. Hertzog, J., et al., Infection with a Brazilian isolate of Zika virus generates 
RIG-I stimulatory RNA and the viral NS5 protein blocks type I IFN 
induction and signaling. European Journal of Immunology, 2018. 48(7): p. 
1120-1136. 
81. Schoggins, J.W., Interferon-stimulated genes: roles in viral pathogenesis. 
Current Opinion in Virology, 2014. 6: p. 40-46. 
82. Goubau, D., S. Deddouche, and C. Reis e Sousa, Cytosolic Sensing of 
Viruses. Immunity, 2013. 38(5): p. 855-869. 
83. Miner, J.J., et al., Zika Virus Infection during Pregnancy in Mice Causes 
Placental Damage and Fetal Demise. Cell, 2016. 165(5): p. 1081-1091. 
84. Hermesh, T., et al., Buying time-the immune system determinants of the 
incubation period to respiratory viruses. Viruses, 2010. 2(11): p. 2541-58. 
85. Goertz, G.P., et al., Functional RNA during Zika virus infection. Virus Res, 
2018. 254: p. 41-53. 
86. Manokaran, G., et al., Dengue subgenomic RNA binds TRIM25 to inhibit 
interferon expression for epidemiological fitness. Science, 2015. 
350(6257): p. 217. 
87. Schuessler, A., et al., West Nile Virus Noncoding Subgenomic RNA 
Contributes to Viral Evasion of the Type I Interferon-Mediated Antiviral 




88. Chang, R.-Y., et al., Japanese encephalitis virus non-coding RNA inhibits 
activation of interferon by blocking nuclear translocation of interferon 
regulatory factor 3. Veterinary Microbiology, 2013. 166(1): p. 11-21. 
89. Donald, C.L., et al., Full Genome Sequence and sfRNA Interferon 
Antagonist Activity of Zika Virus from Recife, Brazil. PLOS Neglected 
Tropical Diseases, 2016. 10(10): p. e0005048. 
90. Xia, H., et al., An evolutionary NS1 mutation enhances Zika virus evasion 
of host interferon induction. Nat Commun, 2018. 9(1): p. 414. 
91. Zhao, B., et al., Structure and function of the Zika virus full-length NS5 
protein. Nat Commun, 2017. 8: p. 14762. 
92. Wang, B., et al., Structure and function of Zika virus NS5 protein: 
perspectives for drug design. Cell Mol Life Sci, 2018. 75(10): p. 1723-
1736. 
93. Grant, A., et al., Zika Virus Targets Human STAT2 to Inhibit Type I 
Interferon Signaling. Cell Host & Microbe, 2016. 19(6): p. 882-890. 
94. Xie, X., C. Shan, and P.-Y. Shi, Restriction of Zika Virus by Host Innate 
Immunity. Cell Host & Microbe, 2016. 19(5): p. 566-567. 
95. Herrlinger, S.A., et al., Establishing Mouse Models for Zika Virus-induced 
Neurological Disorders Using Intracerebral Injection Strategies: 
Embryonic, Neonatal, and Adult. J Vis Exp, 2018(134). 
96. Miller, L.J., et al., Zika Virus Infection in Syrian Golden Hamsters and 




97. Hirsch, A.J., et al., Zika virus infection in pregnant rhesus macaques 
causes placental dysfunction and immunopathology. Nature 
Communications, 2018. 9(1): p. 263. 
98. Dudley, D.M., et al., A rhesus macaque model of Asian-lineage Zika virus 
infection. Nat Commun, 2016. 7: p. 12204. 
99. Chen, J., et al., Zika virus infects renal proximal tubular epithelial cells with 
prolonged persistency and cytopathic effects. Emerging Microbes & 
Infections, 2017. 6(1): p. 1-7. 
100. Diteepeng, T., et al., Proteomic analysis of monkey kidney LLC-MK2 cells 
infected with a Thai strain Zika virus. Arch Virol, 2019. 164(3): p. 725-737. 
101. Diteepeng, T., et al., Proteomic analysis of monkey kidney LLC-MK2 cells 
infected with a Thai strain Zika virus. Archives of Virology, 2019. 164(3): p. 
725-737. 
102. Sakinah, S., et al., Repeated infections of dengue (serotype DENV-2) in 
lung cells of BALB/c mice lead to severe histopathological consequences. 
Pathogens and Global Health, 2018. 112(5): p. 259-267. 
103. Thepparit, C. and D.R. Smith, Serotype-Specific Entry of Dengue Virus 
into Liver Cells: Identification of the 37-Kilodalton/67-Kilodalton High-
Affinity Laminin Receptor as a Dengue Virus Serotype 1 Receptor. Journal 
of Virology, 2004. 78(22): p. 12647-12656. 
104. Adams, A.P., et al., Pathogenesis of Modoc virus (Flaviviridae; Flavivirus) 





105. Leyssen, P., et al., Acute encephalitis, a poliomyelitis-like syndrome and 
neurological sequelae in a hamster model for flavivirus infections. Brain 
Pathol, 2003. 13(3): p. 279-90. 
106. Tesh, R.B., et al., Experimental yellow fever virus infection in the Golden 
Hamster (Mesocricetus auratus). I. Virologic, biochemical, and 
immunologic studies. J Infect Dis, 2001. 183(10): p. 1431-6. 
107. Tesh, R.B., et al., Persistent West Nile virus infection in the golden 
hamster: studies on its mechanism and possible implications for other 
flavivirus infections. J Infect Dis, 2005. 192(2): p. 287-95. 
108. Vorou, R., Zika virus, vectors, reservoirs, amplifying hosts, and their 
potential to spread worldwide: what we know and what we should 
investigate urgently. International Journal of Infectious Diseases, 2016. 
48: p. 85-90. 
109. Reagan, R.L., et al., Effect of Zika Virus and Bwamba Virus in the Cave 
Bat (Myotus lucifugus). Transactions of the American Microscopical 
Society, 1955. 74(1): p. 77-79. 
110. Schountz, T., et al., Immunological Control of Viral Infections in Bats and 
the Emergence of Viruses Highly Pathogenic to Humans. Frontiers in 
immunology, 2017. 8: p. 1098-1098. 
111. Schountz, T., Immunology of Bats and Their Viruses: Challenges and 
Opportunities. Viruses, 2014. 6(12): p. 4880-4901. 
112. Davis, A., et al., Experimental and natural infection of North American bats 




113. Reagan, R.L. and A.L. Brueckner, Studies of Dengue Fever Virus in the 
Cave Bat (Myotus Lucifugus). The Journal of Infectious Diseases, 1952. 
91(2): p. 145-146. 
114. Fagre, A.C. and R.C. Kading, Can Bats Serve as Reservoirs for 
Arboviruses? Viruses, 2019. 11(3): p. 215. 
115. Kading, R.C. and T. Schountz, Flavivirus Infections of Bats: Potential Role 
in Zika Virus Ecology. The American journal of tropical medicine and 
hygiene, 2016. 95(5): p. 993-996. 
116. Machain-Williams, C., et al., Serologic Evidence of Flavivirus Infection in 
Bats in the Yucatan Peninsula of Mexico. JOURNAL OF WILDLIFE 
DISEASES, 2013. 49(3): p. 684-689. 
117. Malmlov, A., et al., Experimental Zika virus infection of Jamaican fruit bats 
(Artibeus jamaicensis) and possible entry of virus into brain via activated 
microglial cells. PLOS Neglected Tropical Diseases, 2019. 13(2): p. 
e0007071. 
118. de Oliveira, R.C., et al., Hantavirus reservoirs: current status with an 
emphasis on data from Brazil. Viruses, 2014. 6(5): p. 1929-1973. 
119. Davis, J.W., J.L. Hardy, and W.C. Reeves, Modoc viral infections in the 
deer mouse Peromyscus maniculatus. Infection and immunity, 1974. 
10(6): p. 1362-1369. 
120. Green, W., et al., Tissue distribution of hantavirus antigen in naturally 




121. Au - Sobczak, M., J. Au - Dargatz, and M. Au - Chrzanowska-Wodnicka, 
Isolation and Culture of Pulmonary Endothelial Cells from Neonatal Mice. 
JoVE, 2010(46): p. e2316. 
122. Li, W.-C., K.L. Ralphs, and D. Tosh, Isolation and Culture of Adult Mouse 
Hepatocytes, in Mouse Cell Culture: Methods and Protocols, A. Ward and 
D. Tosh, Editors. 2010, Humana Press: Totowa, NJ. p. 185-196. 
123. Engelmann, G.L. and J.A. Fierer, Preparation of primary monolayer 
cultures of adult rat hepatocytes. Journal of tissue culture methods, 1982. 
7(4): p. 169-173. 
124. Seglen, P.O., Chapter 4 Preparation of Isolated Rat Liver Cells, in 
Methods in Cell Biology, D.M. Prescott, Editor. 1976, Academic Press. p. 
29-83. 
125. Laishes, B.A. and G.M. Williams, Conditions Affecting Primary Cell 
Cultures of Functional Adult Rat Hepatocytes: II Dexamethasone 
Enhanced Longevity and Maintenance of Morphology. In Vitro, 1976. 
12(12): p. 821-832. 
126. Paine, A.J., L.J. Williams, and R.F. Legg, Apparent maintenance of 
cytochrome P 450 by nicotinamide in primary cultures of rat hepatocytes. 
Life sciences, 1979. 24(23): p. 2185-2191. 
127. Williams, G.M., E. Bermudez, and S. Dominick, Rat Hepatocyte Primary 
Cell Cultures. III. Improved Dissociation and Attachment Techniques and 





128. Williams, G.M., et al., Rat Hepatocyte Primary Cultures IV. Maintenance in 
Defined Medium and the Role of Production of Plasminogen Activator and 
Other Proteases. In Vitro, 1978. 14(10): p. 824-837. 
129. Seglen, P.O., Preparation of rat liver cells: II. Effects of ions and chelators 
on tissue dispersion. Experimental Cell Research, 1973. 76(1): p. 25-30. 
130. Seglen, P.O., Preparation of rat liver cells: III. Enzymatic requirements for 
tissue dispersion. Experimental Cell Research, 1973. 82(2): p. 391-398. 
131. Williams, G.M., E. Bermudez, and D. Scaramuzzino, Rat hepatocyte 
primary cell cultures. In Vitro, 1977. 13(12): p. 809-817. 
132. Aparicio-Vergara, M., et al., Isolation of Kupffer Cells and Hepatocytes 
from a Single Mouse Liver. Methods in molecular biology (Clifton, N.J.) 
Journal Article, 2017. 1639: p. 161. 
133. Diamond, M.S., Mechanisms of evasion of the type I interferon antiviral 
response by flaviviruses. J Interferon Cytokine Res, 2009. 29(9): p. 521-
30. 
134. Suthar, M.S., S. Aguirre, and A. Fernandez-Sesma, Innate Immune 
Sensing of Flaviviruses. PLOS Pathogens, 2013. 9(9): p. e1003541. 
135. Munoz-Jordan, J.L., et al., Inhibition of interferon signaling by dengue 
virus. Proc Natl Acad Sci U S A, 2003. 100(24): p. 14333-8. 
136. Viney, M. and E.M. Riley, The Immunology of Wild Rodents: Current 





137. Zhou, P., et al., Contraction of the type I IFN locus and unusual 
constitutive expression of IFN-α in bats. Proceedings of the National 
Academy of Sciences, 2016. 113(10): p. 2696-2701. 
138. Baker, M.L., T. Schountz, and L.-F. Wang, Antiviral Immune Responses of 
Bats: A Review. 2013. 60(1): p. 104-116. 
139. Zhou, P., et al., Type III IFNs in Pteropid Bats: Differential Expression 
Patterns Provide Evidence for Distinct Roles in Antiviral Immunity. The 






















APPENDIX A  






















Note: Acronyms and their definitions are listed out in the order they are 
encountered within the text. 
ZIKV: Zika virus  
GBS: Gullian Barré syndrome 
CZS: Congenital Zika virus syndrome 
IFN: Interferon 
Arboviruses: Athropod-borne viruses  
YFV: Yellow fever virus  
JEV: Japanese encephalitis virus  
TBEV: Tick-borne encephalitis virus  
WNV: West Nile virus  
RNA: Ribonucleic acid  
GAGs: Glycosaminoglycans  
E protein: Envelope protein  
C: Capsid protein  
PrM: Pre-membrane protein 
M: Membrane protein 
RLR’s: Retinoic acid-inducible gene-I-like receptors  
DNA: Deoxyribonucleic acid  
mRNA: Messenger ribonucleic acid 
RT-qPCR: Reverse transcriptase-quantitative polymerase chain reaction 
DC: Dendritic cells  




MOIs: Multiplicity of Infections  
PAMPS: Pathogen associated molecular patterns  
PRRs: Pattern recognition receptors  
MAVS: Mitochondrial antiviral signaling adapter 
TBK1: Tank Binding Kinase 1 
ISRE: IFN-stimulated response elements  
ISG: Interferon stimulated genes  
sfRNA: Subgenomic flaviviral RNA 
PARP: Poly ADP ribose polymerase 
LGTV: Langat virus  
SPOV: Spondweni virus  
PCR: Polymerase Chain Reaction 
MODV: Modoc virus  
SLEV: St. Louis encephalitis virus  
PFU: Plaque forming unit  
PRNT: Plaque reduction neutralization test  
SQ: Subcutaneous 
IP: Intraperitoneal  
SOP: Standard operating procedure  
PC: Pulmonary cell  
DMEM: Dulbecco’s Modified Eagle Medium 
DPBS: Dulbecco’s phosphate-buffered saline  




hpi: Hours post infection 
TCID50: Tissue culture infectious dose 50  
CPE: Cytopathic effect  
ANOVA: Analysis of variance  

















































Note: Prior to any work, all animals were euthanized per colony protocols and 
none of the thesis work was done on live animal models. Therefore, no additional 
protocols were necessary. The ARF has a colony protocol for bats and a holding 
protocol was used briefly for the hamsters. The Hawkinson lab has a lab protocol 




























To: Dr. Ann Hawkinson 
From: Laura Martin, Director of Compliance and Operations 
CC: IACUC Files 
Date: 3/4/16 
Re: IACUC Protocol 1502B-AH-DM-18 Annual Renewal Approval 
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18. 
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vertebrate animals at the University of Northern Colorado. 
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